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ABSTRACT 
 Pancreatic cancer is a nearly uniformly lethal disease, with the five-year survival 
rate remaining a dismal five percent.  Recently, our laboratory has associated the loss of 
SMAD4, a critical mediator of TGF-β and BMP signaling, with the presence of widely 
disseminated pancreatic cancer.  Therefore, we sought to obtain a better understanding of 
these pathways in the biology of pancreatic cancer through analysis of SMAD4 loss and 
SMAD6 elevation. 
 To gain a better understanding of the role of SMAD4 loss in pancreatic cancer, 
we established isogenic cell lines from pancreatic cancer cells that were SMAD4-
deficient, such that these cell lines were SMAD4-complemented.  We were able to show 
that restoration of SMAD4 into these cell lines hindered their ability to proliferate, 
migrate, and invade through matrigel in vitro.  Furthermore, we sought to gain an 
understanding of the utility of SMAD4 as a marker for the efficacy of chemotherapy.  We 
have shown that SMAD4 status is predictive of a small, but statistically significant, in 
vitro response to cisplatin and irinotecan and resistance to gemcitabine. 
 Second, we identified SMAD6, previously described as an inhibitor of both TGF-
β and BMP, as being differentially expressed in pancreatic cancer cell lines and tissues.  
SMAD6 expression was found not to be regulated by genetic mutation or degree of RNA 
transcription, but through aberrant proteolytic degradation.  It is through loss of this 
regulatory mechanism that SMAD6 expression becomes elevated, leading to increased 
levels of proliferation, migration, and invasion through matrigel, in vitro, and increased 




TGF-β and BMP signaling, we have determined that the effects of SMAD6 on pancreatic 
cancer cells are independent of this function.  Rather, we have identified a nuclear role 
for SMAD6: SMAD6 is able to bind to DNA in pancreatic cancer, and is constitutively 
located in the nucleus of pancreatic cancer cells. 
 Therefore, both SMAD4 loss and SMAD6 overexpression negatively impact the 
biology of pancreatic cancer, albeit through different mechanisms.  Further study will 
continue to elucidate the role of these proteins in the biology of pancreatic cancer. 
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 Pancreatic ductal adenocarcinoma (hereafter referred to as pancreatic cancer) is an 
almost uniformly lethal disease – it was estimated that eighty-five perfect of patients 
diagnosed with pancreatic cancer in 2012 succumbed to their disease (1).  Its five-year 
survival rate of merely five percent has remained constant over many years; as such, 
pancreatic cancer is the fourth-leading cause of cancer-related death in the United States 
(1,2). 
 The dire statistics attributed to pancreatic cancer are due, largely, to two major 
factors.  First, there currently are no effective and established screening modalities for 
pancreatic cancer (3).  Surgery, the only potentially curative treatment for pancreatic 
cancer, is not an option for up to eighty percent of patients due to the advanced stage at 
which their diagnosis occurred (4-6).  As such, there has been fervent interest in 
developing techniques to catch pancreatic cancer at an early stage.  Recent studies 
suggest progress in the discovery of pancreatic cancer biomarkers.  A panel of 
microRNAs, in combination with CA19-9, has shown preliminary effectiveness in 
distinguishing the blood of patients with pancreatic cancer from that of healthy 
individuals (7).  In addition, methylation of two particular genes, BNC1 and ADAMTS1, 
in serum has shown promise in the detection of early stage pancreatic cancer (8). 
Aside from the hurdle of detecting pancreatic cancer while the disease is in a 
manageable state, effective non-surgical means for treating the disease remain limited.  
Gemcitabine, the chemotherapeutic standard of care for managing pancreatic cancer, is 
not particularly effective on its own (4,6,9).  Recent studies have indicated that 




erlotonib, Nab-paclitaxel, capecitabine, and docetaxel (10-12).  In addition, recent 
success has been reported using a combination of oxaliplatin, irinotecan, fluorouracil, and 
leucovorin (FOLFIRINOX) (13).  Furthermore, most patients who undergo surgical 
resection of their pancreatic cancer eventually have disease recurrence (14).  As such, 
there is significant interest in the development of improved adjuvant treatment regimens 
– including chemotherapy and radiation strategies – to lower this probability (14,15). 
 
Pancreatic Cancer Progression and Genetics 
 Pancreatic cancer develops through several known precursor lesions, including 
mucinous cystic neoplasms (MCNs), intraductal papillary mucinous neoplasms (IPMNs), 
and pancreatic intraepithelial neoplasias (PanINs), with the latter being the most common 
of the three (16).  PanINs form in the smallest pancreatic ducts and are characterized by 
increasing morphological changes from PanIN1 to PanIN3 lesions (17-19).  PanIN 
lesions have also been characterized genetically; the alterations that are known to occur at 
each stage are discussed below. 
 Both targeted and global sequencing studies in pancreatic cancer have revealed 
four genes that are mutated at particularly high frequency in pancreatic cancer.  The 
predominant mutation that is known to drive pancreatic cancer progression occurs in 
KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) in codons 12 and 13 (20-
22).  Mutations in this gene occur in up to 99% of pancreatic cancers (21,22).  KRAS 
encodes a GTPase known to activate many downstream pathways, including mitogen-
activated protein kinase and phosphoinositol-3 kinase networks (reviewed in (23)).  Of 




mutation.  The next most common genetic event in pancreatic cancer is the inactivation 
of the cyclin-dependent kinase inhibitor CDKN2A/p16 (cyclin-dependent kinase inhibitor 
2A), through mutation along with allelic loss, homozygous deletion, or promoter 
hypermethylation (24-26).  Mutations in KRAS and CDKN2A are found in early PanIN 
lesions (PanIN1-2), with KRAS believed to be the first mutation of the two to occur (27).   
 Conversely, mutations in the other driver genes in pancreatic cancers tend to 
occur as late as PanIN3 (28,29).  Loss of TP53 (tumor protein 53) function occurs 
through point mutation or small intragenic deletion in three-quarters of pancreatic cancers 
(30,31).  This protein is a tumor suppressor involved in many cellular functions 
(reviewed in (32)).  SMAD4/DPC4 is the final common alteration in pancreatic cancer, 
with mutations or homozygous deletions occurring in 55% of cases (33).  Mutations in 
SMAD4 cause the protein to be rapidly degraded (34).  Therefore, immunohistochemistry 
for the presence or absence of SMAD4 is commonly used to assess SMAD4 status in 
pancreatic cancer patients (35).  SMAD4 is a transcription factor necessary for TGF-β 
and BMP signaling (36,37).  It is worth noting that additional members of these two 
pathways have been found to harbor mutations at low frequencies in pancreatic cancer 
(21,22,38,39). 
 Interestingly, the mutations that occur in the aforementioned genes are not 
random.  Loss of SMAD4 tends to occur in cancers that also harbor TP53 alterations, 
suggesting that TP53 loss precedes that of SMAD4 (40).  Furthermore, the types of 
mutations observed in these genes are closely linked to each other.  SMAD4 loss tends to 
occur in association with TP53 missense mutations, whereas cancers with wild-type 




deletions of TP53 (40).  Further research is needed to parse out the true meaning behind 
these genetic patterns. 
 
Pancreatic Cancer Metastasis 
 While the genetic events that are associated with early-stage pancreatic cancer 
have been well-characterized, the alterations leading to the metastatic dissemination of 
pancreatic cancer are not well understood.  As such, our laboratory established the 
Gastrointestinal Cancer Rapid Medical Donation Program (GICRMDP) at Johns Hopkins 
in 2003 in order to better study the events that underlie end-stage pancreatic cancer (41).  
As part of this IRB-approved program, rapid autopsies are performed, on average, eight 
hours post-mortum on consenting gastrointestinal cancer patients, including those that 
have suffered from pancreatic cancer.  As part of the autopsy, primary tumor tissue, 
metastatic lesions, and normal samples are collected and saved for downstream analysis.  
Several important observations regarding pancreatic cancer metastasis have arisen from 
the research associated with this program.  First, there are two distinct patterns of 
metastasis in pancreatic cancer patients: approximately two-thirds of patients display 
widespread metastasis at autopsy, while the remaining patients have a more localized 
disease (42).  Of the patients with widespread disease, the most common sites of 
metastasis are the liver, peritoneum, and lung, although the disease will rarely spread to 
bone, the adrenal glands, as well as other sites. 
 In addition, the genetics of pancreatic cancer metastasis have become clearer 
through the study of pancreatic cancer autopsy samples.  Alterations of TP53 and SMAD4 




Yachida and colleagues, through whole-exome sequencing of seven patients’ primary and 
metastatic lesions, were able to better elucidate the process and timing of pancreatic 
cancer metastasis (43).  Through a comparison of the mutations in the metastases and 
their corresponding primary cancers, a genetic progression model could be established for 
each patient.  Comparative lesion sequencing revealed that genetically discrete subclones 
exist within the primary tumor, leading to the formation of distinct distant metastases 
(43,44).  Furthermore, based on a calculated proliferative rate and the number of 
mutations found in each lesion, a timeline of pancreatic cancer formation was able to be 
gleaned.  The development of the parental clone of the tumor takes nearly twelve years, 
the formation of metastatic subclones takes an additional seven years, and the formation 
of frank, distant metastases takes an additional three years.  All in all, the time from 
pancreatic cancer initiation to death is approximately twenty-one years, leaving a large 
window of opportunity for clinical intervention (43). 
 
Transforming Growth Factor-beta (TGF-β) and Bone Morphogenetic Protein 
(BMP) Signaling  
 As previously stated, SMAD4, one of the major driver genes of pancreatic cancer, 
is a central mediator of TGF-β and BMP signaling (36).  These pathways, which 
comprise the TGF-β superfamily of signaling, are summarized in Figure 1.  Global 
sequencing analyses have confirmed these pathways to be among the most highly 




the TGF-β and BMP tracts, each of which relay their signal through similar kinase 
cascades.   
 TGF-β ligands bind to TGF-β receptor II (TGF-βRII), which is a constitutively 
active serine-threonine kinase (45,46).  This event stimulates the formation of a complex 
between TGF-βRII and TGF-β receptor I (TGF-βRI); upon complex formation, TGF-
βRII phosphorylates TGF-βRI, activating the latter, which is also a serine-threonine 
kinase (45,47).  Upon presentation to TGF-βRI by the Smad anchor for receptor 
activation (SARA), the substrates of TGF-βRI, SMAD2 and SMAD3 (referred to as R-
SMADs) are phosphorylated (47-50).  These effectors then dissociate from SARA and 
bind to SMAD4 in the cytoplasm (33,36,47,49,50).  This complex then enters the nucleus 
and is able to bind to SMAD-binding elements in the promoter regions of DNA in 
conjunction with other transcription factors (37,51,52). 
The BMP pathway proceeds in a similar manner.  BMP ligands bind to type II 
receptors in concert with type I receptors, much like their TGF-β counterparts (53-56) 
The BMP-specific R-SMADs, SMAD1, SMAD5, and SMAD8, are subsequently 
phosphorylated after presentation to the receptor by ENDOFIN (57-61).  Upon 
association with SMAD4, the R-SMAD heteromeric complexes enter the nucleus to 
affect transcription (36,57,60). 
It should be noted that TGF-β and BMP signaling are both tightly regulated 
within cells.   A large number of endogenous antagonists have been identified for both 
pathways, acting at several points along the pathways under several different 
mechanisms, including mimicking receptors, competitively binding pathway components, 




transcription activating complex to a repressive complex (62-85).  These inhibitors, along 
with specific functions of each, are listed in Table 1.  
 
TGF-β and BMP Signaling in Pancreatic Cancer 
SMAD4 was originally identified based on its frequent deletion in pancreatic 
cancer (its original name is Deleted in Pancreatic Cancer, Locus 4) (33).  Further research 
has indicated that SMAD4 mediates suppression of cell proliferation through the 
activation of the cell cycle inhibitors p21/waf1 and p15/ink4b (86-88).  In addition, the 
modulation of SMAD4 levels in pancreatic cancer cells has caused a reduction in growth 
rate and angiogenesis using a xenograft model (89-91).  Furthermore, SMAD4 has been 
shown to reduce the degree to which pancreatic cancer cells are able to migrate and 
invade in response to TGF-β in vitro, with the latter potentially affected by a decrease in 
MMP-2 and MMP-9 production (90,92).  Gene expression studies confirm that SMAD4 
loss causes changes in the gene expression patterns of several relevant pathways: 
cytoskeleton remodeling, cell cycle regulation, and proliferation (86).  Thus, the 
perturbation of TGF-β and BMP signaling through SMAD4 loss affects pancreatic cancer 
cells in numerous ways that could contribute to the progression of pancreatic cancer.  
Furthermore, multiple studies have implicated SMAD4 loss with a worse prognosis in 
pancreatic cancer (93,94).   
 These observations suggest that loss of TGF-β and BMP signaling through 
SMAD4 mutation or deletion is an oncogenic event in pancreatic cancer.  However, more 




pancreatic cell media with TGF-β promoted epithelial-to-mesenchymal transition and 
enhanced the production and activity of the pro-metastatic factors matrix-
metalloproteinase 2, urokinase plasminogen activator, and urokinase plasminogen 
activator receptor (95-98).  Pharmacological inhibition of TGF-β receptors inhibited the 
migration and invasion of COLO-357 and BxPC3, but not Panc1, pancreatic cancer cells 
(99,100).  Similarly, mice harboring KRAS and TP53 mutations in their pancreata 
displayed accelerated PanIN and pancreatic cancer formation when treated with a TGF-β 
neutralizing antibody (101).  Furthermore, the mice in which TGF-β was blocked had 
more rapidly proliferating tumors and reduced surivival compared to control mice.  These 
results confirm those of Rowland-Goldsmith et al., who showed that inhibiting TGF-β 
signaling in a xenograft model of pancreatic cancer blocks tumor growth, angiogenesis, 
and metastasis (102).  In patients, mutation of TGF-βRII does not affect survival, while 
an elevated presence of TGF-β ligands confers a poor prognosis (93,103).   
BMP modulation also yields conflicting results.  The treatment of pancreatic 
cancer cells with BMP-2 has a SMAD-4 dependent effect on proliferation rate – BMP-2 
increased the proliferation of the SMAD4-deficient cell lines, AsPC -1 and Capan1, 
decreased the proliferation of the SMAD4-intact cell line, COLO-357, and had no effect 
on the SMAD4-intact cell lines MiaPaCa2, Panc1, and T3M4 (104).  These changes in 
cell proliferation were rescued by the complementation (AsPC-1 and Capan1) or 
inhibition (COLO-357) of SMAD4 in these cell lines.  Most of what is known regarding 
the effect of BMP on cell motility has been shown in the Panc1 cell line.  Treatment of 
Panc1 with BMP-2, -4, or -7 stimulated an epithelial-mesechymal transition (105-107).  




production of MMP-2 (106).  However, loss of BMPR1A has been shown to negatively 
impact patient survival, more closely mirroring loss of SMAD4 (93,94,108). 
 
SMAD6 
 One inhibitor of TGF-β and BMP signaling, SMAD6, has been of particular 
interest since its cloning in 1997 (74,109).  This inhibitory SMAD was originally 
identified to bind TGF-β and BMP type I receptors in a ligand-dependent manner, 
subsequently inhibiting the phosphorylation of SMAD1 and SMAD2, but not SMAD3 
(74).  As such, SMAD6 inhibited the activity of the TGF-β-specific luciferase reporter, 
p3TP-Lux (74,109).  However, additional studies called into question the ability of 
SMAD6 to inhibit TGF-β signaling.  Hata et al. determined that SMAD6 expression 
inhibited the transcription of SMAD1 target genes, but not those of SMAD2 (75).  
Furthermore, this group did not observe a change in p3TP-Lux activity, while a BMP-
specific luciferase reporter showed a significant reduction (75).  While some refer to 
SMAD6 as being BMP-specific in its actions, it has been shown to affect TGF-β 
signaling as well (110,111). 
 The mechanisms through which SMAD6 has been proposed to inhibit signaling 
through the TGF-β superfamily are varied.  SMAD6 interacts with BMPR1 and TGF-βRI 
in vitro (74,75,77).  It is thought that SMAD6 recruits the ubiquitin ligase, SMURF1, to 
the type 1 receptors, facilitating their degradation (77).  Furthermore, SMAD6 was shown 




them for degradation, as well.  In addition, SMAD6 was able to bind to SMAD1, 
inhibiting its binding to SMAD4 (75).  
In addition to these cytoplasmic mechanisms for SMAD6 function, there exists a 
nuclear component, as well.  SMAD6 was found to bind to several transcriptional co-
repressors, including HOXC8, HDAC1, and CTBP (76,112,113).  When in complex with 
these factors, SMAD6 is able to act as part of the repressive complex through its MH1 
domain (112).  Target genes for SMAD6-mediated repression include ID1, ID2, 
Osteopontin, and HHEX (76,113,114).  SMAD6 has also been shown to interrupt the 
DNA-binding ability of additional transcription factors, including DLX3 and TBX6 
(115,116).  Additional “non-canonical” functions of SMAD6 include inhibition of the 
Wnt and NFκB signaling (117,118) 
Of particular interest to us, SMAD6 has been previously associated with 
pancreatic disease.  Mice overexpressing this protein in their pancreatic acinar cells were 
more susceptible to developing pancreatitis, which is considered a risk factor for 
pancreatic cancer (119,120).  In pancreatic cancer, SMAD6 has been shown to have 
elevated expression at the RNA level (110).  Overexpression of SMAD6 in COLO-357 
pancreatic cancer cells increased anchorage independent growth, while suppressing TGF-
β mediated growth inhibition.  In other cancer models, SMAD6 increases cell growth and 
clonogenicity of non-small-cell lung cancer cells, while reducing survival (111).  
Furthermore, a SNP in SMAD6 is associated with increased probability of brain 




Given our interest in the metastasis of pancreatic cancer and our prior association 
of SMAD4 loss with widely metastatic disease (42), we sought to better characterize the 
effects of TGF-β and BMP pathway loss on the biology of pancreatic cancer.  Herein, we 














Table 1.  Functions of endogenous TGF-β and BMP inhibitors. 
Protein Function Reference 
PIN1 Induces degradation of SMAD2/3 by recruitment of 
SMURF2 
(62) 
SMURF1 Induces ubiquitination of SMAD1/5/8, TGF-βRI (63,64) 
SMURF2 Induces degradation of SMAD2, TGF-βRI (65,66) 
NEDD4-2 Induces degradation of SMAD2, TGF-βRI (67) 
WWP1 Induces degradation of TGF-βR1 (68) 
CHIP Induces degradation of SMAD1 (69) 
JAB1 Induces degradation of SMAD4 (70,72) 
ROC1 Induces degradation of SMAD3 (73) 
SMAD6 Inhibits phosphorylation of SMAD1/2; competitively 
binds SMAD4; induces BMPRI degradation; represses 
BMP-mediated transcription 
(74-77) 
SMAD7 Inhibits phosphorylation of SMAD2/3; induces 
degradation of TGF-βRI 
(64,66,78) 
STRAP Stabilizes interaction between SMAD7 and TGF-βRI (72) 
BAMBI Kinase-deficient Type I Receptor decoy (79) 
SKI Converts nuclear SMAD complex from activating to 
repressive 
(80-82) 
SNO Converts nuclear SMAD complex from activating to 
repressive 
(83,84) 























 SMAD4 was originally identified based on its frequent deletion in pancreatic 
cancer samples (33) and was later confirmed to be one of the major genes altered in the 
progression of the disease (21,22).  Many studies have been dedicated to gleaning the 
consequences of SMAD4 loss in pancreatic cancer, both clinically and in model systems.  
SMAD4 loss has been associated with an increase in metastasis (42) and a corresponding 
shortening of survival in pancreatic cancer patients (93,94).  It makes sense, then, that in 
vitro, SMAD4 loss has been associated with more aggressive behavior (87-90,92).   
 Curiously, while the downstream members of TGF-β signaling seem to have a 
clear effect on pancreatic cancer cells, the contribution of upstream components is not as 
easily discerned.  One would assume that loss of TGF-β signaling, in general, would 
confer a similar result to loss of SMAD4.  However, this assumption does not necessarily 
hold true.  Mutation of TGF-βRII does not affect prognosis of pancreatic cancer patients, 
while an elevated presence of TGF-β ligands is associated with reduced survival 
(93,103).  Experimentally, the role of TGF-β in pancreatic cancer has been poorly 
understood.  Supplementing pancreatic cell media with TGF-β promoted epithelial-to-
mesenchymal transition and enhanced the production and activity of the pro-metastatic 
factors matrix-metalloproteinase 2, urokinase plasminogen activator, and urokinase 
plasminogen activator receptor (95-98).  Along these lines, the treatment of pancreatic 
cancer cell lines and xenografts with a soluble TGF-β receptor II results in reduced 
invasion in vitro and blocks tumor growth, angiogenesis, and metastasis in vivo (99,102).  
In light of the seemingly contrasting effects of inhibiting SMAD4 and TGF-β 




promotes the switch of TGF-β from a tumor-suppressor to a tumor-promoter (122).  It is 
interesting to speculate that alternative pathways may be activated by TGF-β ligand if the 
signal is unable to be propagated through its traditional cascade.  Several “SMAD-
independent” TGF-β pathways have been identified, including Rac, RhoA, CDC42, ERK, 
JNK, p38, TAK1, NFκB, Pi3K, and Par6 (123-128).  It is possible that TGF-β signals are 
detoured through one of these alternative networks upon loss of SMAD genes in 
pancreatic cancer.  Herein, we describe the effects of SMAD4 loss on pancreatic cancer 





Materials and Methods 
Cell culture.  All cell lines were maintained in Dulbecco’s Modified Eagle Medium 
containing 1 g/L glucose (Gibco, Carlsbad, CA), 10% Fetal Bovine Serum (Gemini Bio-
Products, West Sacramento, CA), 1% Penicillin/Streptomycin (Quality Biological, 
Gaithersburg, MD), and 5 µg/mL Plasmocin (Invivogen, San Diego, CA).   BxPC3 was 
purchased from the American Type Culture Collection, while Pa01 and Pa02 were 
generated in our laboratory. 
Cell transfection.  All transfections were performed using the Attractene lipofection 
system (Qiagen, Valencia, CA). 
Generation of stably transfected cell lines.  Cells were transfected with an empty vector 
(pcDNA3.1) or a SMAD4 plasmid (pcDNA3.1-DPC4) (obtained from Dr. Scott Kern).  
Stably transfected cells were maintained by selection with 0.35 mg/mL G418 sulfate.  
Experiments were performed using either the native transfected cells or cell lines grown 
from a single cell of the parental isogenic lines. 
Polymerase chain reaction.  RNA was extracted from cell lines using the RNEasy Mini 
Kit (Qiagen, Valencia, CA), and five hundred nanograms of RNA was converted to 
cDNA using the Thermoscript RT-PCR system (Invitrogen, Carlsbad, CA).  PCR for 
SMAD4 and β-Actin was performed using standard methods and the primers listed in 
Table 2.  Amplicons were analyzed by agarose gel electrophoresis. 
Luciferase assays. Cells were transiently co-transfected with a construct containing a 
firefly luciferase reporter under the control of a normal (p6SBE) or mutant Smad-binding 




(129).  0.01 mg/mL human TGF-β1 (Sigma, St. Louis, MO) was added to the cell 
medium approximately five hours after transfection.  Luciferase activity was measured 45 
hours after addition of TGF-β1 using a Wallac 1420 plate reader (Perkin Elmer, 
Waltham, MA) and normalized to Renilla luciferase activity. 
Western blotting.  Isogenic clones were exposed to 5 ng/mL hTGF-β1 for 24 hours.  Cells 
were then lysed in 1X RIPA buffer containing a cocktail of protease inhibitors. Protein 
concentration was determined by bicinchoninic acid protein assay (Pierce, Rockford IL), 
and thirty nanograms of total protein was loaded onto a 4-12% Bis-Tris polyacrylamide 
gel and transferred onto a nitrocellulose membrane. Antibody conditions are described in 
Table 3.  Signal was detected using the ECL-Plus kit (GE Healthcare, Piscataway, NJ).  
Patient samples. Patient samples were obtained from consenting patients undergoing 
surgical removal of pancreatic cancers at Johns Hopkins Hospital.  
Immunohistochemistry. Immunolabeling for p-p44/42 and pAKT was performed using 
standard methods and the antibody conditions in Table 4. For pAKT, cancer tissue was 
given an intensity score between 0-3, and cases with a score greater than 2 were deemed 
“high.” For pERK, histology score was calculated.  Those cases with a score greater than 
100 were considered “high.” SMAD4 status was determined by the presence or absence 
of signal. 
Cell proliferation analysis. 2,500 Pa01-Control or Pa01-DPC4 cells/well were seeded in 
96-well plates and allowed to adhere overnight.  At the time of plating, twenty-four, 
forty-eight, seventy-two, and ninety-six hours after transfection, cells were treated with 
10 μL of CCK8 solution (Dojindo, Rockville, MD) and incubated at 37
o




Absorbance at 490 nm was measured using a Wallac 1420 plate reader (Perkin Elmer, 
Waltham, MA). 
Migration and invasion analysis.  Migration and invasion were measured by Boyden 
chamber analysis (BD Biosciences, San Jose, CA).  50,000 Pa01-Control or Pa01-DPC4 
cells were plated onto Boyden chambers (untreated for migration, covered in matrigel for 
invasion) in media containing 0.5% FBS.  After 24 hours, the inserts were subjected to a 
0.5% to 10% FBS gradient.  Cells were allowed to migrate or invade through matrigel for 
48 hours.  At the endpoint of the experiment, cells having migrated or invaded were fixed 
and stained using Diff-Quik (Siemens, Deerfield, IL).  Cells were counted in three 
independent fields per chamber using an inverted microscope at 10X magnification. 
Statistical analysis.  Statistical analyses were performed using SISA, Microsoft Excel, 






Establishment of Cell Lines Stably Complemented with SMAD4 
 In order to study the effect of SMAD4 loss on pancreatic cancer biology, we 
sought to generate stable isogenic cell lines (control and SMAD4-complemented) using 
three parental cell lines, Pa01, Pa02, and BxPC3, all of which contain homozygous 
deletions of SMAD4 (21,130).  Cells were transfected either with an empty vector 
(“Control”) or a plasmid containing full-length, wild-type SMAD4 (“DPC4”) and 
selected with G418 sulfate (131).  The generation of stable cell lines was confirmed using 
semi-quantitative PCR for SMAD4 transcript (Figure 2A), as well as a luciferase assay for 
TGF-β activity (Figure 2B).  SMAD4 transcript was detected in two out of the three cell 
lines attempted: we were successfully able to complement SMAD4 into Pa01 and 
BxPC3, but not Pa02 (Figure 2A).  Despite successfully complementing SMAD4 into 
Pa01 and BxPC3, the change in TGF-β response in these cell lines is minimal (Figure 
2B). Thus, we can infer that, either, an additional factor is blocking TGF-β activity in 
these cell lines or that there is heterogeneity among these cells in regards to the 
transfection efficiency.  These observations will be addressed further in Chapter 4. 
 
SMAD-independent pathways and their relationship with SMAD4 in pancreatic cancer. 
Much of what we understand of TGF-β signaling is through analyses of the 
canonical, SMAD-dependent cascade.  However, TGF-β ligands have been shown to be 




pathways (Rac, RhoA, and CDC42) (123,124), mitogen-activated protein kinase 
pathways (ERK, JNK, and p38) (123-125), NFκB (126), Pi3K (127), and Par6 (128).   
Given the prior observations that modulation of TGF-β receptor levels cause the 
opposite phenotype than modulation of SMAD4 (93,95-99,102,103), we hypothesized 
that these receptors act independently, to some degree, of their canonical downstream 
mediators.  For example, in pancreatic cancers where SMAD4 is lost, it is conceivable 
that TGF-β ligand will stimulate its receptors to signal down an alternative pathway.   To 
address this possibility, we analyzed the activity of several SMAD-independent pathways 
in our SMAD4-isogenic cell lines.  As shown in Figure 3, the p44/42 mitogen-activated 
protein kinase pathway (ERK) and Pi3K/AKT pathways are both preferentially activated 
in the absence of SMAD4.  It is worth noting that the activation of ERK in Pa01 was 
TGF-β ligand-independent, whereas it was somewhat ligand-dependent in BxPC3 cells.  
Genetically, the major difference between these two cell lines is the maintenance of wild-
type KRAS in BxPC3, which is an upstream activator of ERK signaling (23).  This 
genetic disparity may explain the difference in pathway activation between the two cell 
lines. 
Given this interesting observation regarding the preferential activation of ERK 
and AKT in the absence of SMAD4, we sought to verify these data in pancreatic cancer 
patients.  To this end, we performed immunohistochemistry for pERK and pAKT in 
surgically resected primary pancreatic cancers with known SMAD4 status.  As shown in 
Table 5 and Table 6, there is no significant association between ERK or AKT activity and 





The effects of SMAD4 restoration on pancreatic cancer cell behavior. 
 Given the association between SMAD4 loss and increased metastasis in 
pancreatic cancer (42), we sought to determine a rationale, in vitro, for these 
observations.  We generated single cell-derived clones from the pooled isogenic cell lines 
established above.  In particular, we focused our studies on the Pa01 cell line, which was 
established from a liver metastasis at rapid autopsy.  The clones chosen for further 
analysis retain expression of the SMAD4 transcript (Figure 4A) and have restored TGF-β 
activity to a greater degree than their parental cell lines (Figure 2B, Figure 4B), 
suggesting that there is heterogeneity among the parental lines. 
 The prior observations that SMAD4 activates cell cycle inhibitors, such as 
p21/waf1 and p15/ink4b, indicates that suppression of cell proliferation is, potentially, a 
major function of the gene (87,88).  Indeed, as shown in Figure 5, the degree to which 
SMAD4-complemented cells proliferate is significantly reduced compared to SMAD4-
negative cells, as expected.  Given that SMAD4 loss was associated with widespread 
metastasis in pancreatic cancer patients (42), we sought to determine the effects of 
SMAD4 modulation on the degree to which pancreatic cancer cells migrate and invade in 
vitro.  Previous work has suggested that SMAD4 does suppress the TGF-β-induced 
migration and invasion of pancreatic cancer cells (132).  We were able to verify the link 
between SMAD4 and cell mobility, although from a cell autonomous perspective: 
restoration of SMAD4 in Pa01 cells dramatically reduced the ability of the cells to 





 Since its discovery, SMAD4/DPC4 has been extensively studied in the context of 
pancreatic cancer.  Both in cell culture models and clinically, SMAD4 loss has been 
associated with more aggressive pancreatic cancer (42,87,88,92-94).  Herein, we have 
confirmed, using an isogenic cell model, the effect of SMAD4 on pancreatic cancer cell 
proliferation (Figure 5), migration (Figure 6A), and invasion (Figure 6B).  Furthermore, 
our results suggest that alternative, SMAD-independent pathways, such as ERK and 
Pi3K, may be preferentially activated in the absence of SMAD4 (Figure 3). 
 Our results show a clear effect of SMAD4 loss on pancreatic cancer cell behanior.  
We have validated prior work showing that SMAD4 loss promotes proliferation of 
pancreatic cancer cells (86-88) (Figure 5), while we have shown a cell-autonomous effect 
of SMAD4 loss on migration (Figure 6A; p<0.0001) and invasion (Figure 6B; p<0.0001).  
These in vitro data support many clinical studies noting an association between SMAD4 
status and pancreatic cancer prognosis and metastatic burden (42,93,94).  Further study 
will attempt to clarify the mechanism through which SMAD4 loss contributes to the 
increased aggressiveness of pancreatic cancer, both in vitro and in vivo.   
 One possibility that we considered was the activation of SMAD-independent 
TGF-β pathways upon SMAD4 loss.  Exposing pancreatic cancer cells to TGF-β ligand 
results in epithelial-to-mesenchymal transition and the production of pro-metastatic 
signals, while blocking all TGF-β signaling is protective against tumor growth in vitro 
and in vivo  (95,96,96-99,102).  Given that TGF-β has previously been shown to activate 




of completely blocking a TGF-β response, SMAD4 loss causes the redirection of the 
TGF-β signal through another pathway.  Through immunoblotting of cell lines isogenic 
for SMAD4 in the presence or absence of TGF-β1, we were able to associate the 
activation of the ERK and Pi3K pathways with SMAD4 loss (Figure 3).  Both of these 
pathways have previously been implicated in the development of pancreatic cancer.  
Inhibition of ERK signaling has been associated with a cell cycle arrest and, possibly, 
increased apoptosis in pancreatic cancer cell lines (133,134).  Active AKT is also a 
survival factor in pancreatic cancer, while is also promotes invasiveness and is associated 
with more poorly differentiated disease (135-137).  However, despite our observations in 
cell culture, we were not able to associate ERK or Pi3K activation with SMAD4 status in 
primary pancreatic cancers (Table 5, Table 6).  Further study will clarify if there is an 
alternative TGF-β network that is selected for in SMAD4-negative pancreatic cancers, 
other than ERK and Pi3K, that would contribute to the progression of pancreatic cancer 





Table 2.  Primer sequences used for semi-quantitative PCR. 
Primer Name Primer Sequence 
SMAD4 Forward 5-TAGGCAAAGGTGTGCAGTG-3 
SMAD4 Reverse 5-CGATGACACTGACGCAAATC-3 
β-Actin Forward 5-GACCCAGATCATGTTTGAGAC-3 






Table 3.  Antiobdies used for immunoblotting. 
Antibody Company Dilution 
p-p44/42 Cell Signaling (Danvers, MA) 1:1000 
t-44/42 Cell Signaling (Danvers, MA) 1:2000 
pAKT Cell Signaling (Danvers, MA) 1:500 
AKT Cell Signaling (Danvers, MA) 1:1000 
GAPDH Cell Signaling (Danvers, MA) 1:5000 






Table 4.  Antibodies used for immunohistochemistry. 
Antibody Company Dilution 
p-p44/42 Cell Signaling (Danvers, MA) 1:100 
pAKT Cell Signaling (Danvers, MA) 1:100 






Figure 2.  Complementation of SMAD4 into Pa01, Pa02, and BxPC3. 
Pa01, Pa02, and BxPC3 cells were stably transfected with either an empty vector 
(pcDNA3.1) or a DPC4 expression vector (pcDNA3.1-DPC4).  A)  Only Pa01-DPC4 and 
BxPC3-DPC4 express SMAD4 (Pa02-DPC4 cells do not), whereas the corresponding 
control cells do not.   B) Isogenic cell lines were analyzed using a luciferase screen for 
TGF-β response. Data is presented such that the wild-type to mutant promoter ratio is set 
to 1 for all cell lines (baseline). TGF-β activity is presented as the fold increase in 
luciferase levels after TGF-β addition to media (SBE + TGF-β/mSBE + TGF-β). Error 








Figure 3.  Effect of SMAD4 restoration on SMAD-independent TGF-β pathways. 
Cells were treated with 5 ng/mL h-TGF-β1 for 24 hours or left untreated.  A) Analysis of 







Table 5.  Relationship between SMAD4 status and ERK pathway activity in primary 
pancreatic cancers. 
 Low p-p44/42 (N=23) High p-p44/42 (N=24) p 
SMAD4 Status    
     Intact 16 12 0.17 
     Lost 7 12  





Table 6.  Relationship between SMAD4 status and AKT pathway activity in primary 
pancreatic cancers. 
 Low pAkt (N=36) High pAkt (N=11) p 
SMAD4 Status    
     Intact 22 6 0.48 
     Lost 14 5  







Figure 4.  TGF-β responsiveness in single-cell SMAD4-isogenic clones. 
Isogenic cell lines were grown from single cells of the parental Pa01 Control and Pa01 
DPC4 cell lines (Figure 2) and analyzed using semi-quantitative PCR for SMAD4 (A) and 
a luciferase screen for TGF-β response (B). Data is presented such that the wild-type to 
mutant promoter ratio is set to 1 for all cell lines (baseline). TGF-β activity is presented 
as the fold increase in luciferase levels after TGF-β addition to media (SBE + TGF-






Figure 5.  The impact of SMAD4 complementation on cell viability. 
Restoration of SMAD4 reduces proliferation in Pa01 cells as soon as one day after 
plating.  Statistical significance was determined by a contrasted ANOVA.  Error bars 






Figure 6.  The effect of SMAD4 complementation on cell migration and invasion. 
A) Restoration of SMAD4 reduces migration in Pa01 cells (p<0.0001).  Error bars 
represent standard deviation.  B) Complementation of SMAD4 reduces invasion through 
matrigel in Pa01 cells (p<0.0001).  Error bars represent standard deviation.  Significance 
of the differences between Control and DPC4 cells was calculated using a Kruskal-Wallis 
















CHAPTER 3.  SMAD4 CONFERS DIFFERENTIAL CHEMOSENSITIVITY ON 













                                                          
1
 This chapter stems from a collaborative paper between our laboratory and the laboratory of Dr. James 
Eshleman, led by Yunfeng Cui.   
2
 Adapted by permission from the American Association for Cancer Research: Cui et al., Genetically 
defined subsets of human pancreatic cancer show unique in vitro chemosensitivity, Clinical Cancer 





 Given the dire prognosis associated with pancreatic cancer, there has been 
significant interest in developing more effective means to treat the disease.  To date, 
gemcitabine remains the standard of care for pancreatic cancer, but is not particularly 
effective on its own; although, its efficacy increases when combined with erlotonib and 
Nab-paclitaxel (9-11).  In addition, the FOLFIRINOX and GTX regimens have shown 
preliminary effectiveness (12,13). 
 The strategy of treating cancer based on its genetic profile has shown promise in 
other cancer types, notably breast cancer and chronic myeloid leukemia (138-140).  In 
pancreatic cancer, success in personalized medicine has, largely, evaded us.  A recent 
study failed to identify synthetically lethal interactions with oncogenic KRAS in 
pancreatic cancer cells (141).  However, a familial pancreatic cancer harboring a PALB2 
mutation was shown to be susceptible to DNA-damaging agents cisplatin and mitomycin 
C, suggesting that the genetic-based guidance of pancreatic cancer therapy is not an 
insurmountable hurdle (142).  Furthermore, preliminary data suggest that PARP 
inhibitors may prove effective in treating familial pancreatic cancers with BRCA2 
mutations, although the translation of this concept to the clinic remains (143-145). 
 We were interested in determining the effect of the major driver mutations 
(KRAS, CDKN2A, TP53, and SMAD4) on the effectiveness of chemotherapeutics in 
pancreatic cancer cell lines.  We took advantage of the availability of cell lines with 
known genotypes (21) and cell lines isogenic for SMAD4 (described in Chapter 2).  
Herein, we, in conjunction with the laboratory of Dr. James Eshleman, describe our 




Materials and Methods 
Human PC cell lines, human pancreatic ductal epithelial cell line, human DPC4/SMAD4 
isogenic PC cell lines, and cell culture.  Thirty-four human pancreatic cancer cell lines 
used in this study were isolated from the tumor samples of patients in Departments of 
Pathology and Oncology, Johns Hopkins School of Medicine.  Among them, nineteen 
cell lines were used for the Discovery Screen and ten cell lines were used for the 
Prevalence Screen of the original PC sequencing study (21).  The sequences of 23,219 
transcripts representing 20,661 protein-coding genes were determined, and somatic 
mutations identified in the discovery and prevalence screen, homozygous deletions, and 
SAGE gene expression data have been published in detail elsewhere (21).  Twelve of the 
patients contributing samples to this study had a family history of the disease, defined as 
having at least two first degree relatives affected with pancreatic cancer.  The use of 
human tissue was approved by the local IRB (John Hopkins University).  All human 
pancreatic cancer cell lines were cultured in MEM medium (Gibco, Grand Island, NY) 
supplemented with 10% Fetal Bovine Serum (FBS) (Gibco), 100 U/ml Penicillin and 100 
ug /ml Streptomycin.  
An HPV transfected normal human pancreatic ductal epithelial cell line (HPDE), 
generously provided by Dr. Ming-Sound Tsao, was also analyzed. Apart from slightly 
aberrant expression of p53, molecular profiling of this cell line has shown that expression 
of other proto-oncogenes and tumor suppressor genes are normal (146). The HPDE cell 
line was grown in keratinocyte serum free-media (Invitrogen, Grand Island, NY) 




Pa01C and Pa02C parental cell lines were both generated from liver metastases of 
PC patients, which both had homozygous deletions of DPC4. Pa01C and Pa02C cells 
were stably transfected with either a cDNA expression plasmid to overexpress DPC4 
(pcDNA3.1-DPC4) or an empty plasmid (pcDNA3.1Mock) using the Attractene 
transfection agent (Qiagen, Valencia, CA). The Pa01C and Pa02C derivative isogenic 
cells were both analyzed as single clones. All of the genetically complemented clones 
express DPC4, while the control cells do not (Figure 4A).  TGF-β pathway activities 
were tested for these isogenic pairs using a previously reported luciferase assay (129).  
These cell lines were cultured in DMEM medium (Gibco) supplemented with 10% FBS 
(Gibco), 100 U/ml Penicillin, 100 ug /ml Streptomycin, and 0.35 mg/mL G418 sulfate 
(Mediatech, Manassas, VA).   All cells were maintained at 37 ℃ in a humidified 
atmosphere with 5% CO2. 
Preparation of anticancer drugs.  Triptolide, docetaxel, MMC, cisplatin, irinotecan and 
artemisinin were purchased from Sigma (St Louis, MO). Gemcitabine was obtained from 
Net Qem (Research Triangle Park, NC). Parp1 inhibitor (KU0058948) was synthesized in 
Dr. Vogelstein’s lab. Artemisinin (an anti-malarial drug) was selected as a negative 
control drug since it possessed no known anticancer activity. The eight drugs were 
dissolved in DMSO (triptolide, docetaxel, cisplatin, irinotecan and artemisinin) or PBS 
(MMC and gemcitabine), stock solutions of 10mM were made and they were stored at -
80 ℃.  
In vitro cell growth assay for drug screening.  Cells were plated in 96-well plates at a 
density of 3,000 cells per well using standard culture media (described above). Edge 




removed and 200 μl of medium with drug was added into each well. Drugs were serially 
diluted to desired final concentrations with medium containing 10% serum and each dose 
had 6 replicate wells. Cells incubated in the medium with the vehicle DMSO or PBS 
served as controls. Plates were incubated with drugs for 72 hours. Media were aspirated 
and each well was washed with PBS 3 times to remove cellular debris. 100 μl of ddH20 
was added to each well and plates were incubated at room temperature for 1 hour to lyse 
the cells. 100 μl of deionized H2O containing 0.15% of SYBR green I solution 
(Molecular Probes, cat # S7567) were added to wells and mixed 10 times. Fluorescence 
was measured by using BMG FluoStar Galaxy (BMG Labtechnologies, USA)(excitation 
at 480 nm and measurement at 520nm) (147).   
Human PC cell lines and HPDE were tested initially at the following doses: 0 nM, 
1 nM, 10 nM, 100 nM, 1 μM, 10 μM and 100 μM. Positive drug effects and isogenic 
cells drugs were tested using final concentrations: 0 nM, 1 nM, 3 nM, 10 nM, 30 nM, 100 
nM, 300 nM, 1 μM, 3 μM and 10 μM in three independent experiments (18 replicate 
wells totally per dose). 
Statistical analysis.  IC50 values were calculated by fitting sigmoid dose-response curves 
with GraphPad Prism 5.0 (GraphPad Software, Inc.). IC50 distributions were compared 
by genetic status (mutations, deletions or both) and family history status with Wilcoxon 
rank sum tests.  A drug response was defined as an IC50 value below the median or 
below the highest IC50 that did not exceed 10,000 (this happened for drugs where more 
than 50% of cell lines had IC50 values greater than or equal to 10,000).  The relationship 




regression model and Fisher’s exact test.  When comparing the IC50 values between 
different drugs or to fold change in pathway activity, Spearman’s rank based correlation 
was used.  IC50 values between isogenic pairs were compared with a paired Student’s t 
test.  Chemosensitivity correlation analysis of clustered cell lines was examined with 
heatmaps and a network map, which is a visual depiction of how cell lines cluster based 
on whether the Spearman correlation of the within-cell line standardized IC50 values 
between a pair of cell lines was 0.65 or higher. Statistical analyses were performed using 
GraphPad Prism 5.0 and R (version 2.13.1). Due to the exploratory nature of the study, p-
values are not corrected for multiple comparisons and are included for descriptive 







Substantial variation of PC cell lines to broad classes of chemotherapeutic agents  
We screened 29 genetically defined pancreatic cancer cell lines with the seven 
broad classes of anticancer drugs listed above. Pancreatic cancer cells were exposed to 
increasing concentrations of the drugs in 6 replicate wells and IC50 values calculated 
(Figure 7). Most pancreatic cancer cell lines were sensitive to gemcitabine, triptolide, 
docetaxel and MMC. The majority of pancreatic cancer cell lines were insensitive to 
cisplatin, irinotecan, Parp1 inhibitor and the negative control drug. Among the generally 
sensitive drugs, some cell lines were notably less sensitive (Figure 8). For example, with 
gemcitabine, the vast majority of cell lines were sensitive with IC50s in the single digit 
nanomolar range, whereas three cell lines (Pa09C, Pa08C and Pa43C) were significantly 
less sensitive (IC50s: 40 to 60 nM). Surprisingly, among the generally ineffective drugs, 
individual cell lines were uniquely sensitive (Figure 9). For example, with cisplatin, most 
cell lines were quite insensitive, whereas a few (Pa18C, Pa21C and Pa228C) had 
relatively lower IC50 values (100 to 200 nM). Similarly, for irinotecan, three cell lines 
(Pa21C, Pa37C and Pa227C) demonstrated IC50 values less than 200nM.  
 
DPC4/SMAD4 inactivation sensitized PC cells to cisplatin and irinotecan but reduced 
their sensitivity to gemcitabine 
We attempted to explain the variation in drug response by correlating it with the 
genetic status of these lines.  We checked all the somatic mutations and homozygous 




screen and the 10 pancreatic cancer cell lines included in the prevalence screen (21). We 
attempted to correlate drug responses to genotype (Figure 10 and Figure 11), considering 
each gene as either mutated only (mut), deleted only (del), mutated or deleted combined 
(md), or wildtype (wt). We initially focused on DPC4/SMAD4.  
Pancreatic cancer cells with DPC4 homozygous deletions were modestly (2-fold) 
more sensitive to cisplatin compared to those with wild type genotype (P=0.04; Figure 11 
and Table 7). Cells with the deletion of any of four SMAD Pathway genes (SMAD3, 
SMAD4, TGF-βR2 or TGF-βR3) were 2.2-fold more sensitive to cisplatin (P=0.02; Table 
7).  In logistic regression analysis, comparisons of DPC4 deleted or SMADPath gene 
defective (mutated or deleted) PC cells to wildtype cells treated with cisplatin confirmed 
this finding (odds ratios: 11.93 and 7.56, P values: 0.01 and 0.05, respectively; Table 8).  
One concern about this study is that of multiple comparisons. Accordingly, to 
confirm these findings, we constructed isogenic cell lines from Pa01C with or without 
homozygous DPC4 deletions (Figure 4). With cisplatin, we found that IC50 values of 
DPC4 deficient cell lines for cisplatin were 1.8-fold and 1.2-fold lower than for DPC4-
containing cell lines (Figure 12A and Table 9). This was less significant in another 
isogenic cell line pair derived from Pa02C, but this cell line showed lower TGF-β 
signaling even when DPC4 was present (Figure 13). Because all the pairs of isogenic 
cells had different levels of TGF-β pathway signaling (Figure 13A), we attempted to 
correlate the cisplatin IC50 values with TGFβ pathway activities in these cells. Our 
results confirmed that IC50 values of cisplatin were positively correlated with TGF-β 
activity (r=0.86, 95%CI: 0.39 to 0.97, P=0.007), although this relationship is largely 




Pancreatic cancer cells with DPC4 defects (mutations or deletion combined) were 
4.5-fold more sensitive to irinotecan than those with wildtype DPC4 (P=0.04; Figure 10 
and Table 7). In logistic regression analysis, comparison of DPC4 defective cells to 
wildtype cells treated with irinotecan produced an odds ratio of 8.64 and a P value of 
0.02, and when only DPC4 deleted cells were compared to wildtype cells, a P value of 
0.02 was obtained (Table 8). In order to verify these findings, we tested the pairs of 
DPC4 isogenic cell lines with irinotecan. We found IC50 values of DPC4 deficient cell 
lines were 1.2-fold and 1.7-fold lower than those of DPC4 complemented cell lines 
(Figure 12B and Table 9). Correlation analysis for IC50 values and TGF-β pathway 
activities was not significant (P=0.067; Table 10). 
We tested two pairs of DPC4 isogenic cells for possible synergy between cisplatin 
and irinotecan at a constant ratio of 1:1 with simultaneous treatment. The combination 
indices (CI) were calculated using CompuSyn (26). Simultaneous treatment with the two 
drugs resulted in antagonistic interactions with DPC4 defective cells and synergistic 
interactions in DPC4 complemented clones at ID50, but these cell lines all showed 
antagonistic or additive interactions at ID75 (Table 11).  
Despite the lack of correlation between DPC4 status and gemcitabine response in 
the panel of pancreatic cancer cell lines (Figure 11), we tested the DPC4 isogenic cell 
lines with gemcitabine, and found that DPC4 defective cells were about 2-fold less 
sensitive than wildtype cells (P=0.058 and 0.033; Figure 12C and Table 9). We made the 
correlation analysis for IC50 values and TGF-β pathway activities in these isogenic cells. 
Our results confirmed that gemcitabine IC50s were negatively correlated with TGF-β 





 As the cost and ease of sequencing falls, the interest in developing personalized 
medicine schema has been rising.  As such, herein, we sought to determine the 
relationship between SMAD4 genetic status and chemosensitivity in vitro, in the hopes of 
establishing SMAD4 as a potential clinical marker to guide treatment.  These studies 
were performed in collaboration with Dr. Yunfeng Cui and Dr. James Eshleman. 
Upon a screen of the cell lines that underwent whole-exome sequencing by Jones 
et al., variability was observed in the sensitivity of cell lines to chemotherapeutics in vitro 
(21,131) (Figure 7, Figure 8, Figure 9).  Because of the frequency at which alterations in 
SMAD4 occur in pancreatic cancer, we were intrigued by the possibility that SMAD4 
status could correspond to therapeutic efficacy of these chemotherapeutic agents.  Indeed, 
the differential sensitivity to cisplatin and irinotecan among the cell lines described above 
was due, in some part, to differences in SMAD4 status (Figure 10, Figure 11, Table 7, 
Table 8).   
The single-cell derived isogenic cell lines described herein were utilized to better 
understand the relationship between SMAD4 and therapeutic efficacy.  SMAD4-
complemented cells were less sensitive to cisplatin (p=0.04, Figure 12A, Table 9) and 
irinotecan (p=0.03, Figure 12B, Table 9) than SMAD4-null cells, while SMAD4-
complemented cells were more sensitive to gemcitabine (p=0.03, Figure 12C, Table 9).  
While these associations were statistically significant, the changes in IC50 values 




proof of principle that a patient’s genotype can potentially guide treatment of his or her 
disease.   
Furthermore, for cisplatin and gemcitabine, in particular, the degree to which the 
isogenic cells were sensitive or resistant to the drugs was correlated to the degree of 
TGF-β pathway activity (Figure 13, Table 10).  These data indicate that factors other than 
SMAD4 may influence the sensitivity of pancreatic cancer cells to these agents, as well.  
It is worth noting that TGF-β signaling was identified as being one of the most commonly 
altered pathway in pancreatic cancer via whole-exome sequencing, although the causative 
mutations differed from patient to patient (i.e. mutations in other SMAD pathway 
members were identified) (21).  As such, it is not surprising that mutations in TGF-βRII 
also conferred resistance to irinotecan (p=0.03, Table 7), while mutations in any TGF-β 
pathway member conferred resistance to cisplatin (p=0.02, Table 7).  Given that SMAD4 
status, clinically, is typically determined by immunohistochemistry rather than 
sequencing (35), SMAD4 is a good candidate for pre-therapy patient stratification.  
However, given the relationship between TGF-β activity and cisplatin and gemcitabine 
efficacy, one must wonder about the degree to which the presence of SMAD4 is 
indicative of pathway activation.  Previous studies have identified a lack of TGF-β 
response in cell lines identified as being wild-type for pathway members as well as in cell 
lines complemented with SMAD4, as herein (148,149).  This issue will be addressed 
further in the next chapter. 
In addition to our studies that correlate SMAD4 status to differential 
chemosensitivity in vitro, recently, independent studies with SMAD4-isogenic cell lines 




target cells lacking SMAD4 (150,151).  These results, certainly, validate our hypothesis 
that SMAD4 status can theoretically be used to stratify patients into certain treatment 
groups.  The benefit to our study is that the agents analyzed are already used in the clinic.  
However, there are limitations to all three studies in that they are solely conducted in 
vitro.  Further experimentation in animal models of pancreatic cancer and eventual 
clinical trials will be necessary to fully understand if stratification by SMAD4 status is an 
appropriate clinical strategy for treatment of pancreatic cancer.  Nonetheless, it is 








Figure 7.  Chemosensitivity of PC cell lines to broad classes of chemotherapeutic 
agents. 
Drug responses (Log10 of the IC50 values) of 34 PC cell lines tested with 7 
chemotherapeutic drugs representing different mechanisms of action, and the control 
drug (artemisinin). Each cell line result is represented by a single circle. Horizontal lines 
indicate the median IC50 value for each drug for all cell lines. The four drugs on the left 







Figure 8.  Responses of individual PC cell lines to gemcitabine. 
Cytotoxic effects of gemcitabine on PC cells. Gemcitabine demonstrated generally good 
responses, although unique cell lines showed more than 100 fold less sensitivities (* 








Figure 9.  Responses of individual PC cell lines to insensitive drugs. 
Cytotoxic effects of cisplatin (A), irinotecan (B) on pancreatic cancer cell viability 
demonstrated variable drug responses, and unique cell lines showed more than 200 fold 







Figure 10.  Correlations of drug response to genotype. 
Cytotoxic effect of irinotecan was related to DPC4/SMAD4 inactivation.  Wilcoxon rank 
sum tests were used to compare differences in the median IC50 by mutation status. “md” 








Figure 11.  Correlations of drug response to DPC4 genotype. 
Cytotoxic effects of cisplatin (A) and irinotecan (B) were related to DPC4/SMAD4 
deletion. Gemcitabine (C, E) and cisplatin (D) (not significant) are included for the DPC4 
mutation status because they have significant different drug responses in DPC4 isogenic 
pairs. Wilcoxon rank sum tests were used to compare differences in the median IC50 by 






Table 7.  Correlation analysis between chemosensitivity and somatic mutations 
alone, homozygous deletion alone, or both in pancreatic cancer cells identified in the 
discovery and prevalence screen 














































* Median (range) IC50 values for drugs by mutation status (mutated/deleted: M+, not 
mutated/deleted: M-).  Ic50 values were truncated at 10000.  P values are for Wilcoxon 
rank sum tests for differences in the median IC50 by mutation status.  Gene names 
followed by “del” indicates a deletion; “md” indicates either a mutation or deletion.  

















95% CI Exact 
p 
Irinotecan SMAD4.md 17 2 5 5 8.62 (1.18, 
63.1) 
0.020 
 SMAD4.del 8 0 14 7 / / 0.020 
Cisplatin SMAD4.del 7 1 8 13 11.93 (1.19, 
119.22) 
0.010 
 SMADPath.md 14 9 1 5 7.56 (0.75, 
76.2) 
0.050 
* Number of cell lines, by gene status (mutated/deleted: M+, not mutated/deleted: M-) 
and drug response (responder: R+, non-responder: R-).  Gene names followed by “del” 
indicates a deletion; “md” indicates either a mutation or deletion.  Odds ratios are from 
logistic regression models for drug response as a function of mutation status.  A drug 
response was defined as an IC50 value below the median.  P values are for Fisher’s exact 
test.  A model was run for each gene/drug combination.  SMADPath includes SMAD3, 
SMAD4, TGFBR2, and TGFBR3.  “/” indicates odds ratio and 95% CI that couldn’t be 





Figure 12.  Responses of isogenic cancer cell lines to anticancer drugs. 
Two pairs of isogenic pancreatic cancer cell lines for DPC4/SMAD4 were tested with 
cisplatin (A), irinotecan (B) and gemcitabine (C). Results for Pa01C isogenic cells are 
shown, as they demonstrate higher TGFβ functional complementation. Differences of 
IC50 value for isogenic pairs were compared with paired t-test analysis and significant P 
values indicated. IC50s were calculated for each experiment using 6 replicates per dose, 
and three separate experiments were used to calculate the mean IC50 for each drug and 






Table 9.  IC50s of DPC4/SMAD4 isogenic cells tested with Cisplatin, Irinotecan, and 
Gemcitabine 

















Cisplatin Pa01C-DPC4-1  + 4.06 1524.00±
259.90 
1.82 0.040 
 Pa01C-Control-1 - 0.86 837.70± 
166.50 
  
 Pa01C-DPC4-2 + 3.35 1055.00±
294.50 
1.23 0.307 










 Pa02C-Control-1 - 1.11 523.00± 
29.69 
  




 Pa02C-Control-2 - 1.12 636.90± 
75.43 
  
Irinotecan Pa01C-DPC4-1  + 4.06 1491.00±
83.81 
1.20 0.077 
 Pa01C-Control-1 - 0.86 1239.00±
24.11 
  














 Pa02C-Control-1 - 1.11 1274.00±
112.40 
  
 Pa02C-DPC4-2 + 1.46 2393.00±
98.52 
1.37 0.044 
 Pa02C-Control-2 - 1.12 1745.00±
48.01 
  
Gemcitabine Pa01C-DPC4-1  + 4.06 4.27± 
0.70 
0.51 0.058 
 Pa01C-Control-1 - 0.86 8.42± 
0.60 
  
 Pa01C-DPC4-2 + 3.35 3.70± 
0.62 
0.47 0.033 










 Pa02C-Control-1 - 1.11 6.77± 
0.14 
  
 Pa02C-DPC4-2 + 1.46 4.73± 
0.69 
0.58 0.186 
 Pa02C-Control-2 - 1.12 8.14± 
1.27 
  









Figure 13.  Association of drug response to TGF-β pathway activity. 
TGF-β pathway activities were tested for DPC4 isogenic pairs using luciferase assay 
(A).Correlations between IC50s of cisplatin (B) or gemcitabine (C) and TGF-β pathway 






Table 10.  Correlation analysis between IC50s of Cisplatin, Irinotecan, and 
Gemcitabine and TGFB pathway activity of DPC4 isogenic cells 
Drug Correlation r 95% confidence 
interval 
P value 
Cisplatin 0.86 0.39 to 0.97 0.007 
Irinotecan 0.07 -0.67 to 0.74 0.067 
Gemcitabine -0.81 -0.96 to -0.25 0.015 





Table 11.  Combination indices (CI) for cisplatin+irinotecan combination in DPC4 
isogenic cell lines 








Pa01C-DPC4-1 Cisplatin + 
Irinotecan 
1:1 Simultaneously 0.66 1.04 
Pa01C-Control-1 Cisplatin + 
Irinotecan 
1:1 Simultaneously 1.31 1.73 
Pa01C-DPC4-2 Cisplatin + 
Irinotecan 
1:1 Simultaneously 0.73 0.93 
Pa01C-Control-2 Cisplatin + 
Irinotecan 
1:1 Simultaneously 4.38 1.91 





















 As described in Chapter 1, one of the major genetic alterations in pancreatic 
cancers is the loss of SMAD4, either through mutation or homozygous deletion 
(21,22,33).  Of the four major driver genes classified in pancreatic cancer, SMAD4 has 
been one of particular interest due to its prognostic significance: cancers harboring 
SMAD4 mutations and deletions metastasize to a higher degree and cause a shortened 
survival compared to cancers with intact SMAD4 (42,93,94,108).   
As would be expected, the TGF-β and BMP pathways, which require SMAD4 to 
function (36), were recently identified as being two of the most commonly altered 
pathways in pancreatic cancer (21).  Mutations in major components of both pathways 
were detected in two large-scale sequencing efforts of pancreatic cancers (21,22).  While 
mutations specific to both pathways were detected, each patient had a maximum of one 
TGF-β superfamily aberration.  Still, there was a preponderance of mutations in SMAD4 
in these cohorts; because of its role in both TGF-β and BMP responsiveness, it is difficult 
to glean information regarding which particular pathway’s loss is selected for during 
pancreatic cancer evolution.  
Given that SMAD4 is necessary for the full activation of canonical TGF-β and 
BMP signaling, we investigated these pathways in greater detail in pancreatic cancer cell 
lines that were previously identified as having all pathway components intact either 
through directed or whole-exome sequencing efforts (21,38).  Herein, we investigate the 









Materials and Methods 
Cell culture.  All cell lines were maintained in Dulbecco’s Modified Eagle Medium 
containing 1 g/L glucose (Gibco, Carlsbad, CA), 10% Fetal Bovine Serum (Gemini Bio-
Products, West Sacramento, CA), 1% Penicillin/Streptomycin (Quality Biological, 
Gaithersburg, MD), and 5 µg/mL Plasmocin (Invivogen, San Diego, CA).  HPNE and 
HPNE-KRAS cells were obtained from Dr. Michel M. Ouelette (152,153).  All other cell 
lines used herein were purchased from the American Type Culture Collection (Capan2, 
MiaPaCa2, Panc1, and Su.86.86) or were established by our laboratory (Pa01, Pa02, 
Pa03, and Pa04). 
Cell transfection.  All transfections were performed using the Attractene lipofection 
system (Qiagen, Valencia, CA). 
Luciferase assays. Cells were transiently co-transfected with a construct containing a 
firefly luciferase reporter under the control of  a normal (p6SBE) or mutant Smad-
binding element (pm6SBE) to measure TGF-β response or a normal (ID1 WT4F luc) or 
mutant (ID1 mutB4F) ID1 promoter to measure BMP response in addition to a construct 
containing a Renilla luciferase reporter (129,154).  0.01 mg/mL human TGF-β1 (Sigma, 
St. Louis, MO) was added to the cell medium approximately five hours after transfection, 
while 300 ng/mL human BMP-2 (eBioscience, San Diego, CA) was added to cell 
medium approximately 24 hours after transfection (154).  Luciferase activity was 
measured 48 hours after transfection using the Dual Luciferase Reporter Assay System 
(Promega, Madison, WI) and a Wallac 1420 plate reader (Perkin Elmer, Waltham, MA) 




Overexpression of KRAS.  HPNE cells were transfected with a construct containing a 
firefly luciferase reporter under the control of  a normal (p6SBE) or mutant Smad-
binding element (pm6SBE) in addition to a construct containing a Renilla luciferase 
reporter (129,154); simultaneously, the cells were transfected with either an empty pBabe 
vector or pBabe-KRas12V (Addgene plasmid 12544) (155).   0.01 mg/mL human TGF-
β1 (Sigma, St. Louis, MO) was added to the cell medium approximately five hours after 
transfection.  Luciferase activity was measured 48 hours after transfection using the Dual 
Luciferase Reporter Assay System (Promega, Madison, WI) and a Wallac 1420 plate 
reader (Perkin Elmer, Waltham, MA) and normalized to Renilla luciferase activity. 
Treatment with U0126. Cells were transiently co-transfected with a construct containing a 
firefly luciferase reporter under the control of  a normal (p6SBE) or mutant Smad-
binding element (pm6SBE) to measure TGF-β response or a normal (ID1 WT4F luc) or 
mutant (ID1 mutB4F) ID1 promoter to measure BMP response in addition to a construct 
containing a Renilla luciferase reporter (129,154).   10 μM U0126 (Cell Signaling, 
Danvers, MA) or an equivalent volume of DMSO was added to cells along with 0.01 
mg/mL human TGF-β1 (Sigma, St. Louis, MO) or 300 ng/mL human BMP-2 
(eBioscience, San Diego, CA).  After six hours, luciferase assays were performed as 
above. 
Western blotting.  Cells were lysed in 1X RIPA buffer containing a cocktail of protease 
inhibitors.  Protein concentration was determined by bicinchoninic acid protein assay 
(Pierce, Rockford IL), and thirty nanograms of total protein was loaded onto a 4-12% 




conditions are listed in Table 13.  Signal was detected using the ECL-Plus kit (GE 
Healthcare, Piscataway, NJ).  
Patient samples.  Patient samples were obtained from consenting patients undergoing 
surgical removal of pancreatic cancers at Johns Hopkins Hospital and from patients 
enrolled in the GICRMDP at autopsy. 
Immunohistochemistry.  Immunolabeling was performed using a 1:500 dilution of anti-
SMAD6 antibody (Invitrogen, Carlsbad, CA) using standard methods.  Cancer tissue was 
given an intensity score between 0-3 with consensus by two authors viewing the slides 
simultaneously at a two-headed microscope, with scores of 2 or greater considered 
“high.”   
RNA isolation and quantitative real-time PCR.  RNA was extracted from cell lines using 
the RNEasy Mini Kit (Qiagen, Valencia, CA), and five hundred nanograms of RNA was 
converted to cDNA using the Thermoscript RT-PCR system (Invitrogen, Carlsbad, CA) 
and diluted ten-fold (twenty-fold for β-actin).  Quantitative real-time PCR was performed 
using an Applied Biosystems 7300 Real-Time PCR System (Carlsbad, CA) and the 
Platinum SYBR Green qPCR Supermix-UDG (Invitrogen, Carlsbad, CA).  Data were 
analyzed by the ΔΔCt method with normalization to β-Actin.  Primer sequences are listed 
in Table 12. 
Treatment of cells with MG132 and western blotting.  Cells were grown to 80% 
confluence in 10 cm dishes and treated with 10 μM MG132 (Sigma, St. Louis, MO) or an 
equal volume of DMSO overnight.  Cells were subsequently lysed and immunoblotting 





Baseline levels of TGF-β and BMP signaling in pancreatic cancer.   
 In order to obtain a better understanding of the degree to which the TGF-β and 
BMP signaling pathways are active in pancreatic cancer, we obtained six cell lines in 
which all components of these two pathways are genetically intact.  Four of these cell 
lines (Capan2, MiaPaCa2, Panc1, and Su.86.86) underwent directed sequencing of 
SMAD and TGF-β receptor genes (38); two additional cell lines (Pa03 and Pa04) were 
included in a cohort for whole-exome sequencing (21).  The degree to which the TGF-β 
and BMP pathways are active in these cell lines was measured using luciferase reporters 
specific for each network.  To measure TGF-β activity, we obtained the p6SBE and 
pm6SBE luciferase reporters, which comprise six copies of the wild-type and mutant 
SMAD-binding element, respectively (129).  To measure BMP activity, we obtained the 
ID1 WT4F and ID1 mutB4F luciferase reporters, which are composed of four copies of 
wild-type and mutant ID1 promoters, respectively (154); ID1 is the classical read-out for 
BMP activity (156). 
 Upon performing the luciferase screen, we observed a striking trend: despite the 
genetically-intact TGF-β and BMP pathways of these cell lines, the degree to which these 
pathways were activated more closely resembled cell lines with a homozygous SMAD4 
deletion than the non-cancerous pancreas cell line, HPNE (Figure 14).  This phenomenon 
was particularly noteworthy for TGF-β, although BMP signaling was also highly variable 





The Impact of Oncogenic RAS on TGF-β and BMP Signaling in Pancreatic Cancer 
 Given the surprisingly low levels of TGF-β and BMP signaling in pancreatic 
cancer cell lines wild-type for the components of these pathways, we hypothesized that 
these networks may be inhibited by another mechanism.  Previous studies by Massagué 
and colleagues had determined that the presence of oncogenic mutations in KRAS 
interfered with the ability of colorectal cancer cells to respond to TGF-β ligand 
(157,158).    It was determined that the MEK-ERK cascade, activated downstream of 
RAS, causes phosphorylation of the linker regions of both TGF-β- and BMP-associated 
R-SMADs, preventing nuclear import of these critical signaling mediators (23,157-159).  
Given the nearly ubiquitous presence of constitutively active KRAS in pancreatic cancer 
(20-22), we sought to determine whether these mutations were contributing to the 
dampened response to TGF-β and BMP in the cell lines used herein.   
 In order to ascertain whether hyperactive KRAS affects pancreatic cancer cells’ 
response to the TGF-β superfamily, HPNE (152) and HPNE-KRAS (153) cells were 
analyzed for TGF-β and BMP response.  HPNE-KRAS cells express a common variant 
of this oncogene in pancreatic cancer, G12D (153).  Contrary to our expectations, the 
presence of KRAS
G12D
 significantly impacted neither TGF-β nor BMP response levels 
(Figure 15A).  In addition, we repeated the TGF-β specific assay after transfecting HPNE 
cells with a different oncogenic KRAS variant, G12V (155).  This variant also failed to 
significantly inhibit TGF-β signaling (Figure 15B).  However, while non-significant, 
KRAS appears to slightly activate TGF-β signaling in these cells (Figure 15).  These data 
imply that the dampening of TGF-β and BMP signaling in pancreatic cancer cells is due 




BMP reporter assays in the presence or absence of U0126, a pharmaceutical MEK 
inhibitor, to inhibit the ERK-mediated phosphorylation of R-SMADs (160).  HPNE, 
MiaPaCa2, and Panc1 cells were treated with U0126 prior to performing the TGF-β and 
BMP reporter assays.  Should ERK be phosphorylating the linker region of R-SMADs to 
inhibit downstream TGF-β and BMP responses, we would expect an increase in the 
activity of these pathways upon treatment with U0126.  While there was a small increase 
in TGF-β activity in MiaPaCa2 (p=0.04), there was, otherwise, no significant change in 
the level of TGF-β (Figure 16A) or BMP signaling (Figure 16B) in these cell lines.  We 
conclude, therefore, that the activating mutations in KRAS that are observed in the 
majority of pancreatic cancers are not substantially impacting the ability of the cancer 
cells to respond to TGF-β and BMP ligands. 
 
The Impact of Endogenous TGF-β and BMP Antagonists on TGF-β and BMP Signaling 
in Pancreatic Cancer 
If RAS is not inhibiting TGF-β and BMP responses in pancreatic cancer cells, 
there likely exists another factor that is impairing these pathways’ activity.  An intriguing 
notion is that an antagonist of the TGF-β and BMP pathways is overexpressed in 
SMAD4-intact cases to compensate for the continued activation of these pathways.  To 
investigate this possibility, we performed western blotting against several known 
inhibitors of TGF-β and BMP signaling to assess their expression in cell lines wild-type 
for TGF-β and BMP pathway components.  Examples of these immunoblots are shown in 




particularly struck by the stark differential expression of SMAD6, an inhibitor of both 
TGF-β and BMP signaling, among these cell lines (74,75).   
Recognizing that cell lines do not always provide an accurate representation of the 
biology of pancreatic cancers in vivo, we sought to verify the expression of SMAD6 
within pancreatic cancer samples.  We performed immunohistochemistry for SMAD6 on 
primary pancreatic cancers from 180 patients (from surgical resection and rapid autopsy) 
and observed a similar disparity in SMAD6 expression (Figure 18).   Out of the cases 
examined, 70.6% displayed strong SMAD6 expression, whereas the remainder showed 
barely detectable levels of the protein.  Therefore, we conclude that SMAD6 expression 
is extremely variable among pancreatic cancer patients.   
 
Analysis of SMAD6 regulation. 
Given our observation that SMAD6 expression is elevated in the majority of 
pancreatic cancers, we considered the possibility of an activating mutation in this gene.  
Previously, a directed sequencing study directed at all SMAD genes did not detect 
SMAD6 mutations in twelve pancreatic cancer cell lines, nor in other tumor types (161).  
Since, there have been two large-scale sequencing efforts in pancreatic cancer, compiling 
genetic data on a combined 123 patients; not a single SMAD6 mutation was identified in 
these cohorts (21,22).  As such, we surmised that SMAD6 mutation is unlikely the cause 
of this gene’s differential regulation.  Therefore, we sought to determine the epigenetic 




 Given that SMAD6 is unlikely to be activated by mutation in pancreatic cancer 
(21,22,161), another logical possibility is that the level of its transcription is being 
aberrantly regulated.  There are several factors known to induce transcription of SMAD6, 
including stimulation with TGF-β1, activin, BMP-2, BMP-7, and EGF (162,163).  These 
data suggest that SMAD6 is activated in response to TGF-β and BMP as endogenous 
negative feedback; consistent with this notion, SMAD6 was not induced by TGF-β or 
BMP ligands in cells lacking SMAD4 (162). 
SMAD6 is transcribed at a baseline level in several normal human tissues, 
including pancreas (74); however, we wished to determine if this expression was 
dysregulated in pancreatic cancer.  Kleeff et al. previously demonstrated an upregulation 
of SMAD6 mRNA in pancreatic cancer cells compared to normal ductal epithelial cells, 
but were unable to correlate levels of SMAD6 transcript to protein (110).  In order to 
determine if the varied SMAD6 levels observed previously are the result of differential 
transcription of this locus in pancreatic cancer, we extracted RNA from Capan2, 
MiaPaCa2, Panc1, Su.86.86, Pa03, and Pa04 cells and performed quantitative real-time 
PCR to measure the levels of SMAD6 RNA.  SMAD6 transcript was detected in all cell 
lines examined, in agreement with prior studies (74,161,162).  However, the levels of 
SMAD6 transcript did not correspond to its protein levels, indicating that control of 
SMAD6 transcription is unlikely the cause of its differential protein expression (Figure 
17, Figure 19).  
 Because SMAD6 does not appear to be regulated at the DNA or RNA level, we 
concluded that regulation via a post-transcriptional mechanism was likely.  To assess this 




Su.86.86, Pa03, and Pa04) with MG132, a peptide aldehyde that functions to inhibit the 
proteasome (164).  Upon treatment with the proteasome inhibitor, SMAD6 protein levels 
were restored in each of these four cell lines (Figure 20).  The difference in size between 
the restored SMAD6 proteins in these cell lines and the endogenous SMAD6 in 
MiaPaCa2 was consistent with SMAD6 being polyubiquitinated.  As such, we are able to 
conclude that aberrant degradation of SMAD6 is, at least, partially responsible for its 









 Through analysis of genetic mutations discovered through whole-exome 
sequencing, the TGF-β and BMP pathways were identified as among those most 
commonly dysregulated in pancreatic cancers (21).  Herein, we have determined that, 
even in cases that would be classified as having unaltered TGF-β and BMP networks by 
genetic analyses, TGF-β and BMP signaling is distorted (Figure 14).  These results 
confirm those of Simeone et al., who noted a lack of TGF-β activation in the MiaPaCa2 
and Panc1 cell lines (148).  Furthermore, Dai and colleagues showed that SMAD4 
restoration into BxPC3 cells did not rescue TGF-β response, but did in a breast cancer 
cell line, MDA-MB-468 (149). This finding is in agreement with our observation that 
SMAD4 complementation has little effect on the TGF-β activity of Pa01 and BxPC3 cells 
(Figure 2B).   
 That the degrees of TGF-β and BMP activity do not correspond to the mutational 
profile determined previously (21,38) suggests that these pathways are being regulated 
both genetically, via mutation or deletion of SMAD4 and other pathway components, and 
epigenetically in pancreatic cancer.  Given the near universal dampening of signaling – 
particularly TGF-β (Figure 14) – we considered the likelihood that constitutively active 
KRAS was the causative factor for this phenomenon (157-159).  Previous studies have 
implicated MEK-ERK activity downstream of RAS in the inhibition of R-SMAD nuclear 
import (157-159).  Given the propensity of KRAS mutations in pancreatic cancer (nearly 
all patients have a mutation in this gene) (20-22), we considered the likelihood that RAS 
signaling was impinging on the SMAD pathways in our model.  However, neither 




SMAD signaling in normal and cancerous pancreatic cell lines (Figure 15, Figure 16).  
The lack of TGF-β response in SMAD4-complemented BxPC3 cells supports these 
results: BxPC3 retains wild-type KRAS, so would not be susceptible to KRAS-mediated 
TGF-β antagonism (149).  The studies that associated oncogenic RAS with TGF-β and 
BMP inhibition were performed in other cell models (157-159).  The possibility exists 
that there are cell-type reasons for this discrepancy. 
 After eliminating oncogenic RAS as a mechanism of TGF-β and BMP 
impediment in pancreatic cancer cells, we considered the option that an endogenous 
antagonist was overexpressed to compensate for the presence of wild-type pathway 
members.  There are many known antagonists of TGF-β and BMP signaling.  These 
factors impact the pathways at varying levels from the membrane to the nucleus.  There 
are several extracellular ligands that prevent the binding of TGF-β and BMP ligands to 
their receptors, including NOGGIN, CHORDIN, and FOLLISTATIN, among others 
(reviewed in (165)).  BAMBI is a kinase-dead version of type I TGF-β receptors (79).  
There are several inhibitors that prevent phosphorylation of R-SMADs by the receptors, 
including SMAD6, STRAP, and SMAD7 (72,74,78).  Many proteins have been identified 
that contribute to the ubiquitin-mediated degradation of pathway components, such as 
SMAD6, SMAD7, PIN1, SMURF1, SMURF2, NEDD4-2, WWP1, CHIP, JAB1, and 
ROC1 (62,64-70,73,77).  Lastly, there are nuclear proteins that complex with SMADs to 
form a repressive, rather than an active, complex on promoter regions: SKI, SNO, 
SMAD6, and PARP-1 (76,80-82,84,85).   
We sought to determine whether any of these inhibitors could factor into TGF-β 




been studied in the context of pancreatic cancer.  SMAD7 expression leads to a more 
aggressive phenotype in pancreatic cancer cell lines, while overexpression of SMAD7 in 
mouse pancreata enhances the formation of PanIN lesions (166,167).  Similarly, 
SMURF1 was found to be amplified in a small subset of pancreatic cancers, leading to 
increased invasion and anchorage-independent growth (168).  However, increased 
expression of SKI correlated with reduced levels of invasion and metastasis (169).  
Therefore, much like TGF-β and BMP signaling, in general, inhibitors of these pathways 
exert varied effects on pancreatic cancer cells. 
 Through immunoblotting for several of these antagonists in our genetically wild-
type cell line panel, we have identified an intriguing differential expression pattern of one 
such inhibitor, SMAD6 (Figure 17).  We were subsequently able to verify this differential 
expression in primary pancreatic cancers (Figure 18).  SMAD6 has previously been 
shown to be overexpressed at the RNA level in a subset of pancreatic cancers (110); here, 
we have shown differential expression of SMAD6 protein for the first time in this cancer 
type.  The previously described functions of SMAD6 are particularly intriguing in 
regards to its overexpression in pancreatic cancer.  Given that SMAD6 can inhibit both 
TGF-β and BMP signaling (74,75), it is intriguing to speculate that SMAD6 may 
phenocopy SMAD4 loss, since SMAD4 is essential for both pathways (36).  
Cancer is frequently thought of as a disease that is fueled by the accumulation of 
genetic mutations (170).  However, there are multiple routes to a gain or loss of function 
of a protein.  For example, as described in this chapter, SMAD6 expression appears to be 
regulated at the post-transcriptional level by aberrant ubiquitination, rather than by 




is furthered by the observation that ubiquitin is, indeed, one of the proteins previously 
found to bind SMAD6 (171). 
 Ubiquitination is a highly conserved biological process present across eukaryotes.  
Ubiquitin, itself, is a relatively small (76 amino acid) protein that is covalently attached to 
lysine residues on target proteins via a C-terminal glycine residue (172).  The process of 
ubiquitination occurs in three steps.  Ubiquitin proteins are activated by E1 enzymes, then 
transferred to a carrier protein, E2 (173).  Finally, E3 catalyzes the adduction of ubiquitin 
onto target proteins.  Polyubiquitin chains (at least four in length) that are attached to 
lysine residues are necessary for recognition by the proteasome (174-176).  
While cancer is, generally, thought to be driven by mutations, altered 
ubiquitination is, by no means, a new phenomenon in the genomic regulation of 
oncogenic processes.  Perhaps the most common cancer protein that is controlled by 
ubiquitination is TP53.  MDM2 is a ubiquitin ligase that controls TP53 stability 
(177,178).  Given its critical role in regulating TP53 function, it is not surprising that 
MDM2 amplification (leading to increased TP53 degradation) has been observed in 
several cancer types (179).  Additional ubiquitin-mediated control of TP53 occurs in 
cervical cancer.  The E6 protein of the human papilloma virus mediates ubiquitin-
mediated destruction of TP53 by the E6-AP ubiquitin ligase (180).  Not only are tumor 
suppressors, such as TP53, lost through over-ubiquitination, oncogenes can be activated 
by loss of ubiquitination, as well.  For example, the epidermal growth factor receptor 
(EGFR), when mutated in glioblastoma, is unable to undergo degradation mediated by 
CBL ubiquitin ligases (181).  Additional ubiquitin-ligases that have been shown to have 




While we have determined that the mechanism for the differential expression of 
SMAD6 is, in part, altered degradation, the causal factor for this phenomenon has yet to 
be identified.  Recently, Zhang et al. performed a screen to identify binding partners of 
SMAD6 (171).  Of those identified, there are many candidates for ubiquitin-mediated 
regulation.  Of the binding partners of SMAD6, several are known to function as part of 
the ubiquitin conjugating cascade.  These proteins include the following E2 and E3 
ligases: SMURF2, ITCH, WWP1, WWP2, UBE2O, UBR4, UBR5 (171).  It is possible 
that the function of one or more of these SMAD6 binding partners is altered in pancreatic 
cancers, leading to the dysregulation of SMAD6 expression.  Furthermore, it should be 
highlighted that, like most biological processes, ubiquitination is reversible.  Additional 
binding partners of SMAD6 include several ubiquitin specific peptidases (USP7, USP9X, 
USP11, and USP34) (171).  This class of proteins is responsible for the rescue of proteins 
from proteolytic degradation (reviewed in (183)).  It is worth noting that several of these 
ubiquitin-modulating factors – both ubiquitin ligases and de-ubiquitinating enzymes – 
have been identified as being mutated in pancreatic cancer (21,22); however, these 
mutations are quite rare.  Therefore, it is plausible that there are a multitude of 
mechanisms through which SMAD6 ubiquitination is altered in pancreatic cancer 
patients.   
 In Chapter 2, we were able to associate the loss of SMAD4 with an increased rate 
of proliferation, migration, and invasion, while previous work has demonstrated an 
association between SMAD4 loss, elevated metastasis, and poor prognosis (42,93,94).  It 
is tempting to assume that SMAD6 elevation phenocopies SMAD4 loss in pancreatic 




on pancreatic cancer, based on prior studies (110,166-169).  The relationship between 




Table 12.  Primer sequences used for real-time PCR. 
Primer Name Primer Sequence 
SMAD6 Forward 5-ACCAACTCCCTCATCACTGC-3 
SMAD6 Reverse 5- CTGCCCTGAGGTAGGTCGTA-3 
β-Actin Forward 5-GACCCAGATCATGTTTGAGAC-3 






Table 13.  Antibodies used for immunoblotting. 
Antibody Company Dilution 
SMAD6 Imgenex (San Diego, CA) 1:500 
PARP-1 Cell Signaling (Danvers, MA) 1:1000 
SKI Santa Cruz Biotechnology (Santa Cruz, CA) 1:500 
SMAD7 Abcam (Cambridge, MA) 1:1000 
STRAP Sigma (St. Louis, MO) 1:500 
Ubiquitin Cell Signaling (Danvers, MA) 1:1000 
GAPDH Cell Signaling (Danvers, MA) 1:5000 







Figure 14.  Luciferase screen for TGF-β and BMP response in pancreatic cancer cell 
lines.  
Data are presented such that the wild-type to mutant promoter ratio is set to 1. TGF-β (A) 
and BMP (B) pathway activity is presented as the fold increase in luciferase levels after 
addition of ligand (e.g. SBE + TGF-β/mSBE + TGF-β).  The genetic status of each cell 
line, determined by either directed or whole exome sequencing (21,38), is indicated.  






Figure 15.  The effect of activated KRAS on TGF-β and BMP activity. 
A) The levels of TGF-β and BMP activity were analyzed in HPNE and HPNE expressing 
the KRAS
G12D
 mutation.  B)  The levels of TGF-β were analyzed in HPNE cells 
transiently transfected with KRAS
G12V
 or an empty vector.  Data are presented such that 
the wild-type to mutant promoter ratio is set to 1. TGF-β and BMP pathway activity is 
presented as the fold increase in luciferase levels after addition of ligand (e.g. SBE + 
TGF-β/mSBE + TGF-β).    Error bars represent standard error of the mean.  Significance 








Figure 16.  The effect of MEK-ERK activity on TGF-β and BMP response. 
Data are presented such that the wild-type to mutant promoter ratio is set to 1. TGF-β (A) 
and BMP (B) pathway activity is presented as the fold increase in luciferase levels after 
addition of ligand (e.g. SBE + TGF-β/mSBE + TGF-β).    Error bars represent standard 







Figure 17.  Expression of TGF-β and BMP antagonists in pancreatic cancer cell 
lines. 
Expression levels of the TGF-β and BMP inhibitors PARP1, SKI, SMAD6, SMAD7, and 
STRAP were determined in six pancreatic cancer cell lines wild-type for all components 








Figure 18.  Expression of SMAD6 in pancreatic cancer tissues. 
Examples of cancers determined to express low levels of SMAD6 (left) and high levels of 








Figure 19.  Relative expression of SMAD6 transcript in pancreatic cancer cell lines. 
Real-time PCR for SMAD6 expression in Capan2, MiaPaCa2, Panc1, Su.86.86, Pa03, and 
Pa04 cells.  Levels are normalized to the expression level in MiaPaCa2.  SMAD6 protein 







Figure 20.  Proteasome inhibition rescues SMAD6 expression.   
Total protein was extracted from MiaPaCa2, Capan2, Su.86.86, Pa03, and Pa04 cells in 
the presence or absence of the proteasome inhibitor, MG132.  Ubiquitin and SMAD6 






















 As described in the preceding chapter, we have identified SMAD6, previously 
classified as an inhibitor of TGF-β and BMP signaling (74,75) as being differentially 
expressed in pancreatic cancer cell lines (Figure 17) and tissues (Figure 18).  
Furthermore, we have determined that SMAD6 is regulated at the protein level, through 
altered proteolytic degradation (Figure 20).  However, it remains to be seen whether 
SMAD6 expression in pancreatic cancers contributes to disease progression. 
 It seems to make sense, given the involvement of SMAD6 in both TGF-β and 
BMP signaling, that overexpression of SMAD6 would phenocopy loss of SMAD4 in 
pancreatic cancer, in that it would lead to increased proliferation (Figure 5), migration 
(Figure 6A), and invasion (Figure 6B) of cancer cells, reduced survival (93,94) and 
increased metastasis in patients (42).  However, the TGF-β and BMP pathways, overall, 
have less clear contributions to the development of pancreatic cancer (93,95-97,99-108).  
Prior studies of the link between SMAD6 and cancer cell behavior are limited.  SMAD6 
was associated with increased proliferation, decreased apoptosis, and a shortened survival 
in non-small cell lung cancer (111), while SMAD6 expression was associated with 
increased anchorage-independent growth in a previous pancreatic cancer study (110).  
Thus, in this chapter, we seek to further define the role that SMAD6 plays – if any – in 





Materials and Methods 
Cell culture.  All cell lines were maintained in Dulbecco’s Modified Eagle Medium 
containing 1 g/L glucose (Gibco, Carlsbad, CA), 10% Fetal Bovine Serum (Gemini Bio-
Products, West Sacramento, CA), 1% Penicillin/Streptomycin (Quality Biological, 
Gaithersburg, MD), and 5 µg/mL Plasmocin (Invivogen, San Diego, CA).  MiaPaCa2 and 
Panc1 cells were purchased from the American Type Culture Collection (Manassas, VA).  
Pa01, Pa03, and Pa04 cells were established by our laboratory. 
Cell transfection.  All transfections were performed using the Attractene lipofection 
system (Qiagen, Valencia, CA). 
Smad6 modulation.  Panc1 and MiaPaCa2 cells were transiently transfected with a 
scrambled shRNA construct as well as a shRNA construct designed to target SMAD6 
(both purchased from Origene, Rockville, MD).  Pa01, Pa03, and Pa04 cells were 
transiently transfected with an empty vector (pcDNA3.1(Hyg)), a SMAD6 vector 
(pcDNA3.1(Hyg)-SMAD6). This overexpression vector was generated through 
subcloning of SMAD6 cDNA purchased from Origene (Rockville, MD) into the 
pcDNA3.1(Hyg) vector (Invitrogen, Carlsbad, CA).  SMAD6 knockdown and 
overexpression was verified 72 hours after transfection by immunoblotting for SMAD6.   
Western blotting.  Cells were lysed in 1X RIPA buffer containing a cocktail of protease 
inhibitors.  Protein concentration was determined by bicinchoninic acid protein assay 
(Pierce, Rockford IL), and thirty-five nanograms of total protein was loaded onto a 4-
12% Bis-Tris polyacrylamide gel and transferred onto a nitrocellulose membrane.  




(GE Healthcare, Piscataway, NJ). For nuclear and cytopasmic extracts, cellular 
subfractionation was performed using the NE-PER Nuclear and Cytoplasmic Extraction 
Reagent (Pierce, Rockford, IL). 
Flow cytometry.  Cells were transfected to knock down SMAD6 as above.  After 72 
hours, cells were stained with Annexin V and propidium iodide using the Annexin 
V/Dead Cell Apoptosis Kit (Molecular Probes, Eugene, OR).  Stained cells were 
analyzed by flow cytometry using a FACSCalibur flow cytometer (BD, Franklin Lakes, 
NJ).  Data were analyzed using CellQuest Pro software (BD, Franklin Lakes, NJ).  
Cell proliferation analysis. Cells were seeded in 96-well plates at a concentration of 
2.5x10
4
 cells/mL and allowed to adhere overnight. Cells were transfected to modulate 
SMAD6 as above.  24, 48, and 72 hours after transfection, cells were treated with 10 μL 
of CCK8 solution (Dojindo, Rockville, MD) and incubated at 37
o
C for three hours. 
Absorbance at 490 nm was measured using a Wallac 1420 plate reader (Perkin Elmer, 
Waltham, MA). 
Migration and invasion analysis.  Migration and invasion were measured by Boyden 
chamber analysis (BD Biosciences, San Jose, CA).  Optimal experimental conditions 
were determined for each cell line. For migration, 25,000 cells (MiaPaCa2, Panc1) were 
plated into uncoated Boyden chambers 24 (MiaPaCa2) or 48 (Panc1) hours after 
transfection with a 0.5% to 10% FBS gradient and allowed to migrate for 48 (MiaPaCa2) 
or 24 (Panc1) hours.  For invasion, 25,000 cells (MiaPaCa2, Panc1) were plated onto 
Boyden chambers coated with matrigel 24 hours after transfection and allowed to invade 




were plated onto Boyden chambers 24 hours after transfection and allowed to invade for 
48 hours towards 50,000 CAF35 cells (Pa03).  At the endpoint of the experiment, cells 
having migrated or invaded were fixed and stained using Diff-Quik (Siemens, Deerfield, 
IL) or hematoxylin and eosin.  Cells were counted in three independent fields per 
chamber using an inverted microscope. 
Patient samples.  Patient samples were obtained from consenting patients undergoing 
surgical removal of pancreatic cancers at Johns Hopkins Hospital and from patients 
enrolled in the GICRMDP at autopsy. 
Immunohistochemistry.  Immunolabeling was performed using the antibodies in Table 15 
using standard methods.  For SMAD6, cancer tissue was given an intensity score between 
0-3 with consensus by two authors viewing the slides simultaneously at a two-headed 
microscope.  Scores of 2 or greater were deemed “high.”  For SMAD4, cancer tissue was 
judged to be positive or negative. 
Luciferase assays.  Pa03 and Pa04 cells were transiently co-transfected with a construct 
containing  a firefly luciferase reporter under the control of  a normal (p6SBE) or mutant 
Smad-binding element (pm6SBE) or a normal (ID1 WT4F luc) or mutant (ID1 mutB4F) 
ID1 promoter in addition to a construct containing a Renilla luciferase reporter (129,154).  
0.01 mg/mL human TGF-β1 (Sigma, St. Louis, MO) was added to the cell medium 
approximately five hours after transfection, while 300 ng/mL human BMP-2 
(eBioscience, San Diego, CA) (154) was added to cell medium approximately 24 hours 




Dual Luciferase Reporter Assay System (Promega, Madison, WI) and a Wallac 1420 
plate reader (Perkin Elmer, Waltham, MA) and normalized to Renilla luciferase activity. 
Chromatin immunoprecipitation.  MiaPaCa2 and Pa03 cells were transiently transfected 
with CS2-FLAG-SMAD6 (Addgene plasmid 14961) (75) using the Attractene reagent 
(Qiagen, Valencia, CA) or left untransfected.  Cells (transfected and untransfected) were 
crosslinked with formaldehyde at a final concentration of 1%.  Chromatin 
immunoprecipitation was performed using the EZ-ChIP kit (Millipore, Billerica, MA).  
Conditions used for pull-down were as follows: 10 μg M2 anti-FLAG (Sigma, St. Louis, 
MO), 1 μg normal Mouse IgG (Millipore, Billerica, MA).  ChIP results were verified 
using quantitative real-time PCR and calculating fold enrichment of FLAG-SMAD6 
transfected samples compared to untransfected samples.  Primers were designed to 
include the predicted SMAD6 binding site on the ID1 promoter (113). 
Trichostatin A treatment.  Pa03 cells were transfected to overexpress SMAD6 as above.  
After 48 hours, either ethanol (vehicle) or 10 ng/mL trichostatin A (TSA) was added to 
the cell media in the presence or absence of 200 ng/mL human BMP-2 (eBioscience, San 
Diego, CA) for 24 hours prior to RNA extraction for qPCR analysis.  Alternatively, Pa03 
and Pa04 cells were transiently co-transfected with SMAD6-overexpression constructs, a 
construct containing a firefly luciferase reporter under the control of a normal (ID1 
WT4F luc) or mutant (ID1 mutB4F) ID1 promoter, and construct containing a Renilla 
luciferase reporter (129,154).  After 48 hours, either ethanol (vehicle) or 10 ng/mL 
trichostatin A (TSA) was added to the cell media in the presence or absence of 300 
ng/mL human BMP-2 (eBioscience, San Diego, CA).  After an additional 24 hours, 




BMP modulation.  MiaPaCa2 cells were treated with 200 ng/mL human BMP-2 
(eBioscience, San Diego, CA), while Pa03 cells were treated with 20 ng/mL anti-BMP-
2/4 antibody (R&D Systems, Minneapolis, MN).  Cell behavior assays were performed as 
above. 
Statistical analysis.  Statistical analyses were performed using SPSS, SISA, and 





The effect of SMAD6 on pancreatic cancer cell properties. 
 In their seminal review and recent update, Hanahan and Weinberg describe the 
general properties that define cancer cells (184,185).  Herein, we have sought to 
determine the effect of modulating SMAD6 expression on these behaviors in pancreatic 
cancer cells, in vitro.   
 Among the hallmarks that Hanahan and Weinberg define of cancer cells are 
“resisting cell death,” “sustaining proliferative signaling,” and “evading growth 
suppressors” (184,185).  In order to determine whether SMAD6 causes these effects in 
pancreatic cells, we modulated the levels of SMAD6 in our pancreatic cancer cell lines 
and determined the resulting change in cell viability.  We transiently knocked down 
SMAD6 in MiaPaCa2 and Panc1 (Figure 21A), which overexpress SMAD6 (Figure 17).  
In addition, we overexpressed SMAD6 in Pa03 cells (Figure 21B), which do not display 
endogenous SMAD6 protein (Figure 17).  As shown in Figure 22, the knockdown of 
SMAD6 in MiaPaCa2 (A) significantly reduced cell replication; conversely, 
overexpression of SMAD6 in Pa03 (C) significantly increased cell number.  SMAD6 
knockdown in Panc1 cells also decreased cell replication, albeit to a lesser extent (Figure 
22B).  While these results suggest that SMAD6 increases cell proliferation, we sought to 
determine if the degree of apoptosis was at all affected upon SMAD6 modulation.  As 
such, we performed flow cytometry for Annexin V levels in MiaPaCa2 and Panc1 cells in 




however, impact the degree of apoptosis in these cell lines, suggesting that its influence 
on cell number is a result of increased proliferation (Figure 23). 
 In addition, we sought to determine the effect of SMAD6 on another hallmark of 
cancer – “activating invasion and metastasis” (184,185).  To determine the effect of 
SMAD6 expression on these properties in vitro, we measured the degree to which cells 
migrate and invade after SMAD6 knockdown or overexpression.  In order to measure 
these properties, we performed migration and invasion assays after transient knockdown 
or overexpression of SMAD6, as above.  Knockdown of SMAD6 significantly impaired 
the ability of MiaPaCa2 (Figure 24A; p=0.0003) and Panc1 (Figure 24B; p<0.0001) cells 
to migrate.  Furthermore, knockdown of SMAD6 significantly impaired the ability of 
MiaPaCa2 (Figure 25A; p<0.0001) and Panc1 (Figure 25B; p<0.0001) cells to invade 
through matrigel, while overexpression of SMAD6 promoted the ability of Pa03 cells to 
invade (Figure 25C; p=0.01).   
 Taken together, these data – that SMAD6 is able to enhance the proliferation, 
migration, and invasion of pancreatic cancer cells in vitro – suggest that SMAD6 is 
acting as an oncogene in pancreatic cancer.   
 
The clinicopathologic relevancy of SMAD6 in pancreatic cancer. 
 Our in vitro data suggests that SMAD6 promotes aggressive pancreatic cancer 
behavior.  To confirm the relevance of SMAD6 in pancreatic cancer, we performed 
immunohistochemistry for SMAD6 on primary pancreatic cancers resected at the Johns 




SMAD6 protein (Figure 18).  Interestingly, SMAD6 expression was not correlated with 
patients’ SMAD4 status (Table 17, p=0.158). 
 In our analyses of our patient cohort, several interesting clinical observations 
could be gleaned.  While SMAD6 status was not correlated to sex, race, age, tumor 
diameter, differentiation status, node ratio, or N-stage, there were significant associations 
to T stage and clinical stage: high SMAD6 was associated with stage T2/T3 tumors 
(p<0.0001) with clinical stages 2A and 2B (p<0.0001; Table 18).  Furthermore, while 
SMAD6 status was not significantly associated with altered prognosis (p=0.486; Figure 
26A), patients whose tumors express high levels of SMAD6 trend toward having reduced 
survival than those with low levels of SMAD6, especially in patients with stage III 
disease (p=0.094; Figure 26B).   
In addition, immunohistochemistry for SMAD6 was performed on primary 
pancreatic cancers obtained from pancreatic cancer patients at rapid autopsy.   In this 
cohort, 63.8% of patients’ tumors had high SMAD6 expression.  SMAD6 levels were, 
again, not associated with the presence or absence of SMAD4 (Table 19, p=0.74).  
Although we did not examine the clinical correlates of SMAD6 expression as with our 
surgical cohort due to the potential compounding variable of treatment, we sought an 
association between SMAD6 status and metastatic burden.  Elevated SMAD6 was linked 
to widespread metastasis at autopsy, regardless of SMAD4 status (Figure 27, p=0.03).  
Thus, overexpression of SMAD6 appears to recapitulate the effects seen by SMAD4 loss 





The Effect of SMAD6 on TGF-β and BMP Signaling in Pancreatic Cancer  
As previously discussed, the classical function of SMAD6 is to inhibit TGF-β and 
BMP signaling (74,75).  In order to identify the role that SMAD6 plays in modulating 
these pathways in pancreatic cancer, we sought to determine the effect of SMAD6 
overexpression on the activation of these pathways.  Given that SMAD6 is a target gene 
of both TGF-β and BMP (162,163), we used our SMAD6 overexpression system to 
perform the studies herein in lieu of our knockdown system.  We transiently transfected 
Pa03 and Pa04 cells to overexpress SMAD6 and performed TGF-β and BMP-specific 
luciferase assays (129,154).  To our surprise, there was no significant change in the 
degree of TGF-β activation upon SMAD6 overexpression (Figure 28A); however, there 
was a consistent and significant decrease of nearly 40% in the level of BMP response 
upon SMAD6 overexpression (Figure 28B).  In order to confirm the inhibition of BMP 
signaling by SMAD6 in these cell lines, we performed immunoblotting for the BMP 
target gene, ID1, in Pa03 and Pa04 cells after SMAD6 overexpression and BMP 
stimulation.  ID1 levels were increased by stimulation with BMP-2, but were diminished 
upon the addition of SMAD6 (Figure 28C), further corroborating the function of SMAD6 
as a BMP inhibitor. 
The mechanisms through which SMAD6 has been proposed to inhibit BMP 
signaling are varied.  It has been suggested that SMAD6 is able to bind to type I BMP 
receptors, specifically ALK-3 and ALK-6 (74,77,186).  As a result of these complexes 
forming, the phosphorylation of downstream R-SMADs is inhibited, potentially via the 
recruitment of SMURF E3 ubiquitin ligases to degrade both the receptors and the R-




transiently transfected Pa03 and Pa04 cells with SMAD6 in the presence or absence of 
BMP-2 ligand and performed immunoblotting for phosphorylated SMAD1/5/8.  We 
observed, however, little noticeable change in the level of phosphorylation of these BMP-
associated R-SMADs upon SMAD6 expression (Figure 29A).  Others have posited that 
SMAD6 interferes with BMP signaling by acting as a transcriptional repressor of BMP 
target genes (76,112,113).  We were particularly intrigued by this mechanism due to our 
observation that SMAD6 is localized in the nuclei of pancreatic cancers in our cohort 
(Figure 18).  To determine if SMAD6, indeed, binds to DNA in pancreatic cancer cells, 
we transfected MiaPaCa2 and Pa03 cells with a FLAG-tagged SMAD6 construct and 
performed chromatin immunoprecipitation (ChIP) against the FLAG tag (75).  ChIP 
revealed enrichment of FLAG on the ID1 promoter in these two cell lines (Figure 29B), 
confirming that SMAD6 does, indeed, bind to the ID1 locus in pancreatic cancer cells.  
Class I histone deacetylases were previously shown to be part of the SMAD6-repressive 
complex (112); to determine whether histone deacetylation mediates the DNA-binding 
function of SMAD6, we assayed for ID1 activation in the presence or absence of the 
histone-deacetylase inhibitor, Trichostatin A (187).  As determined by luciferase assay, 
inhibition of histone deacetylases does not affect the degree to which ID1 is transcribed 
(Figure 29D).  Therefore, the mechanism of SMAD6 in the nucleus appears to be 
independent of histone deacetylases in pancreatic cancer, although SMAD6 does appear 
to be interfering with BMP-induced ID1 expression through acting as a transcriptional 
repressor. 
Therefore, we have shown the SMAD6 increases the aggressiveness of pancreatic 




the effects of BMP modulation on MiaPaCa2 and Pa03 cells through activation of BMP 
(to mirror SMAD6 knockdown) or inhibition of BMP (to mimic SMAD6 
overexpression).  Knockdown of SMAD6 in MiaPaCa2 yielded decreased proliferation 
(Figure 22A) and invasion (Figure 25A); we predicted stimulation of these cells with 
BMP to yield similar changes.  However, BMP promoted proliferation of MiaPaCa2 cells 
(Figure 30A) and did not significantly affect invasion (Figure 30C).  Overexpression of 
SMAD6 in Pa03 cells increased both proliferation (Figure 22C) and invasion (Figure 
25C).  Yet, treatment of Pa03 with a BMP-2/4 neutralizing antibody failed to 
significantly impact either behavior (Figure 30B, D).  These data suggest that BMP 
inhibition is not the mechanism through which SMAD6 impacts pancreatic cancer.  To 
further confirm this observation, we overexpressed SMAD6 in Pa01 cells, which harbor a 
homozygous deletion of SMAD4 (21) and have no measurable BMP signaling (Figure 
14B).  Since there is no BMP signaling to inhibit, we would expect overexpression of 
SMAD6 to have no effect of these cells.  In spite of this hypothesis, SMAD6 
overexpression significantly increased the migration of Pa01 (Figure 30F; p=0.0002), 
although proliferation was not affected (Figure 30E).  Thus, SMAD6 impacts cell 
behavior independently of its ability to inhibit BMP. 
 In light of our observations that SMAD6 performs outside of TGF-β and BMP 
inhibition in pancreatic cancer, we sought to determine its true function in the disease. In 
addition to inhibiting TGF-β and BMP signaling, SMAD6 has been proposed to inhibit 
Wnt and NFκB signaling (117,118,188).  However, we have shown that SMAD6 acts to 
promote pancreatic cancer aggressiveness, whereas these two pathways also are 




SMAD6 is acting through inhibition of either of these networks.  As previously 
discussed, that SMAD6 is able to bind to DNA and repress transcription (76,112,113), 
and we have confirmed that SMAD6 binds to the promoter of the BMP target gene, ID1 
(Figure 29B).   
In order to gain a better understanding of the nuclear function of SMAD6, we 
performed subcellular fractionation of MiaPaCa2 and Panc1, the two cell lines that 
overexpress SMAD6, in the presence or absence of BMP-2 ligand.  We then assessed the 
levels of SMAD6 in the cytoplasm and nucleus of these lysates.  As shown in Figure 
31A, SMAD6 is constitutively present in the nuclei of these cell lines, and remains 
largely unchanged upon BMP-2 stimulation.  To confirm the perpetual presence of 
SMAD6 in the nucleus of pancreatic cancer cell lines, we repeated the subcellular 
fractionation experiments using cell lines that had been transiently transfected to 
overexpress SMAD6.  In Pa03 and Pa04 cells, SMAD6 was, again, expressed in both the 
cytoplasm and nucleus regardless of BMP stimulation (Figure 31B).  These results are in 
agreement with the observations of Bai et al. and Lin et al. (76,113) and further the 
notion that the nuclear function of SMAD6 in pancreatic cancer does not require BMP.  








 SMAD6 has classically been described as an inhibitor of TGF-β and BMP 
signaling (74,75).  As such, one would expect its overexpression in pancreatic cancer to 
mirror the effects of SMAD4 loss, as the latter is a common mediator to both TGF-β and 
BMP pathways (36).  Indeed, in this chapter, we have demonstrated that SMAD6 
promotes proliferation, to some degree, (Figure 22), migration (Figure 24), and invasion 
(Figure 25) of pancreatic cancer cells in vitro and increases the level of metastasis in 
pancreatic cancer patients (Figure 27).  Previous research has indicated that SMAD6 
promotes aggressive behavior in lung cancer cells (111).  Therefore, it appears that 
SMAD6 overexpression at least partially phenocopies SMAD4 loss and is an oncogenic 
event in pancreatic cancer. 
Thus, as discussed in Chapter 4, SMAD6 is likely targeted for degradation under 
normal conditions; this ubiquitination is, then, lost to cause increased protein expression 
in a subset of pancreatic cancer (Figure 20).  Given the degree to which ubiquitination is 
disrupted in human cancer, there has been interest in targeting the Ubiquitin-proteasome 
pathway as part of cancer treatment.  Bortezomib, which inhibits the 20S proteasome, is 
currently FDA-approved for the treatment of several cancer types, and there are new 
drugs in this class in development (reviewed in (193)).  However, one must wonder about 
the efficacy of such agents.  Given the effects of SMAD6 overexpression in pancreatic 
cancer caused by a loss of this protein’s degradation, one would presume that inhibition 
of the proteasome, in general, would result in the aberrant activation of SMAD6 and 




nutlins, which disrupt MDM2-mediated TP53 degradation (194), would be less risky 
forms of cancer treatment. 
Of the four principal genes known to be mutated in pancreatic cancer – KRAS, 
CDKN2A, TP53, and SMAD4 – only KRAS contains a gain-of-function mutation.  As 
such, oncogenic KRAS is the only known pancreatic cancer driver that is, in theory, 
directly targetable.  However, attempts to target KRAS have been unsuccessful, to date.  
Recently, screens for drugs that are synthetically lethal in the presence of KRAS 
mutations were unsuccessful in pancreatic cancer cells (141).  Accordingly, there has 
been significant interest in the determination of alternative targets in pancreatic cancer.  
SMAD6 could fit this profile.  It is present in 70.6% of pancreatic cancers studied herein, 
and is able to enhance proliferation (Figure 22), migration (Figure 24), and invasion 
(Figure 25) in vitro, while it is associated with tumor stage in in pancreatic cancers at 
surgery (Table 18) and correlates with increased metastasis at autopsy (Figure 27).  While 
SMAD6 status was not indicative of a difference in survival in patients overall (Figure 
26A), in late-stage cancers (Stage III), there is a trend toward a disadvantage in survival 
for SMAD6-high patients (Figure 26B).  Given the low percentage of patients whose 
tumors do not overexpress SMAD6, it is possible that the expansion of our cohort will 
yield more conclusive evidence about the role of SMAD6 in pancreatic cancer prognosis. 
Despite our observations in this chapter that SMAD6 contributes to the 
development of pancreatic cancer, the mechanism through which SMAD6 acts in 
pancreatic cancer is, as of yet, unknown.  In a previous study in non-small cell lung 
cancer, Jeon et al. identified many pathways and processes that were altered upon 




which support our experimental observations (111).  In order to further study the 
mechsnism of SMAD6 action in pancreatic cancer, we first assessed its contribution to 
inhibition of TGF-β superfamily signaling.  While prior studies have indicated that 
SMAD6 inhibits TGF-β signaling in pancreatic cancer (110), we sought to verify whether 
SMAD6 affects TGF-β, BMP, or both pathways in our pancreatic cancer model.  
Through the use of luciferase reporters specific for both networks, we conclude that BMP 
is the target pathway of SMAD6 in pancreatic cancer cells, rather than TGF-β (Figure 
28); we were able to validate these data through immunoblotting for the BMP target 
gene, ID1, in the presence or absence of SMAD6 and BMP-2 (Figure 28C).  While 
SMAD6 did not affect the degree to which BMP-associated R-SMADs were 
phosphorylated (Figure 29A), we were able to detect SMAD6 on the promoter of ID1 via 
ChIP (Figure 29B).  Previous work has shown that SMAD6 is able to bind to DNA 
through its MH1 domain and repress BMP-mediated transcription via complexing with 
histone deacetylases (HDACs) and additional transcriptional repressors, such as HOXC8 
and CTBP (76,112,113).  However, we were not able to associate the SMAD6-mediated 
repression of ID1 transcription with HDAC function (Figure 29D).  Still, it appears that 
SMAD6 is modulating BMP responses through repression of target gene transcription in 
pancreatic cancer. 
 In order to further study the association between BMP signaling and SMAD6 in 
pancreatic cancer, we sought to mimic SMAD6 overexpression through inhibition of 
BMP signaling.  In Pa03 cells, overexpression of SMAD6 led to an increase in 
proliferation and invasion in vitro (Figure 22D, Figure 25C).  However, inhibition of 




30B,D).  Similarly, in MiaPaCa2, in which SMAD6 knockdown reduced proliferation 
and invasion (Figure 22A, Figure 25A), activation of BMP signaling did not affect the 
invasive potential (Figure 30C), while it increased the proliferative rate (Figure 30A).  
Limited prior studies have examined the effect of BMP on pancreatic cancer cell 
behavior.  However, activation of BMP has previously been associated with more 
aggressive behavior of Panc1 cells (105-107).  We have shown SMAD6 knockdown to 
result in the opposite effects in this cell line (Figure 22B, Figure 24B, Figure 25B). To 
further delineate the relationship between SMAD6 and BMP signaling in pancreatic 
cancer, we determined the effects of SMAD6 expression in the SMAD4-null cell line, 
Pa01 (21).  While SMAD6 did not affect the proliferation of Pa01 cells (Figure 30E), it 
significantly increased these cells’ migratory capacity (Figure 30F; p=0.0002).  Finally, 
we noted that the expression of SMAD6 in patients was not predicated on the presence of 
SMAD4 (Table 17, Table 19).  These data caused us to question whether BMP inhibition 
is the mechanism through which SMAD6 functions in pancreatic cancer. 
 While the BMP-specific functions of SMAD6 in the nucleus are not likely to be 
affecting pancreatic cancer cell behavior, we remain intrigued by the nuclear function of 
this protein.  We and others have shown that SMAD6 is constitutively located in the 
nucleus, regardless of BMP stimulation (76,113) (Figure 31).  While it has been shown 
that SMAD6 represses BMP-mediated transcription, the possibility remains that there are 
other target genes that SMAD6 regulates in a BMP-independent manner.  Further work 





 In conclusion, we have determined that SMAD6 overexpression is associated with 
aggressive properties of pancreatic cancer – proliferation, migration, and invasion – in 
vitro, while we have associated SMAD6 protein levels with elevated metastasis in 
pancreatic cancer patients.  However, the mechanism through which SMAD6 appears to 
be acting is not through its canonical role of BMP inhibition.  Rather, we sought to 
determine if the presence of SMAD6 in the nucleus of pancreatic cancer cells 
significantly impacted pancreatic cancer biology.  Given that SMAD6 has been shown to 
have the capacity to repress transcription, it is worth noting that the levels of ID1 are 
reduced upon SMAD6 overexpression and SMAD6 binds to the promoter region of this 
gene.  We have determined that SMAD6 is constitutively present in the nucleus of 
pancreatic cancer cells.  Further study will clarify the nuclear role of SMAD6 in 







Table 14.  Antibodies used for immunoblotting. 
Antibody Company Dilution 
SMAD6 Imgenex (San Diego, CA) 1:500 
ID1 Santa Cruz Biotechnology (Santa Cruz, CA) 1:500 
p-SMAD1/5/8 Cell Signaling (Danvers, MA) 1:1000 
t-SMAD1/5/8 Santa Cruz Biotechnology (Santa Cruz, CA) 1:1000 
LAMIN A/C Cell Signaling (Danvers, MA) 1:1000 
GAPDH Cell Signaling (Danvers, MA) 1:5000 





Table 15.  Antibodies used for immunohistochemistry. 
Antibody Company Dilution 
SMAD6 Invitrogen (Carlsbad, CA) 1:500 






Table 16.  Primer sequences used for Chromatin Immunoprecipitation 
Primer Name Primer Sequence 
ID1 ChIP Forward 5- ACAGTCCGTCCGGGTTTTAT -3 







Figure 21.  SMAD6 modulation in pancreatic cancer cell lines. 
Transient modulation of SMAD6 in MiaPaCa2, Panc1, and Pa03 cells were verified 72 
hours after transfection by immunoblotting for SMAD6.  SMAD6 was successfully A) 








Figure 22.  Effect of SMAD6 on pancreatic cancer cell proliferation. 
Differences in cell viability were determined by MTT assay after SMAD6 knockdown.   
Knockdown of SMAD6 reduces cell viability in A) MiaPaCa2 and, to a lesser extent, B) 
Panc1 cells.  C)  Differences in cell viability were determined by MTT assay after 
SMAD6 overexpression.  Overexpression of SMAD6 increases cell viability in Pa03 








Figure 23.  Effect of SMAD6 on apoptosis. 
The levels of apoptosis were determined in MiaPaCa2 and Panc1 cells 72 hours after 
transfection of shSMAD6 by flow cytometry for Annexin V.  There is little change in the 






Figure 24.  Effect of SMAD6 on pancreatic cancer cell migration. 
Differences in cell migration capacity were determined after SMAD6 knockdown.  For 
both A) MiaPaCa2 and B) Panc1, cells displayed reduced migration after SMAD6 
knockdown (p=0.0003 and <0.0001, respectively; Student’s t-test).  All error bars 







Figure 25.  Effect of SMAD6 on pancreatic cancer cell invasion. 
Differences in cell invasion capacity were determined after SMAD6 knockdown.  For 
both A) MiaPaCa2 and B) Panc1, cells displayed reduced invasion after SMAD6 
knockdown (p <0.0001 for both; Student’s t-test).  C) Differences in cell invasion 
capacity were determined after SMAD6 overexpression. Cells overexpressing SMAD6 
displayed a significantly greater invasion than control cells (p=0.01; Student’s t-test).  All 






Table 17.  Relationship between SMAD4 status and SMAD6 status in primary pancreatic 
cancers. 
 Low SMAD6 N=(27) High SMAD6 (N=52) p 
SMAD4 Status 
     Intact 














Table 18.  Clinicopathologic features of SMAD6 expression surgically resected 
pancreatic cancers. 
 Low SMAD6 (N=40) High SMAD6 (N=104) p 
Age at diagnosis (years) 63.60 ± 12.683 67.76 ± 10.843 0.105 
Sex 
     Male 










     White 
     Black 











Tumor Diameter (cm) 3.358 ± 1.4381 3.505 ± 1.4538 0.339 
Differentiation 
     Well 
     Moderate 












     1A 
     1B 
     2A 
     2B 
















     T1 
     T2/T3 











     N0 










     Less than 0.3 









* Significance was calculated using student’s t-test (age and tumor diameter), Fisher 
exact analysis (race, differentiation, clinical stage, T stage, and N stage), and Chi-square 









Figure 26.  The impact of SMAD6 on pancreatic cancer prognosis. 
A) Kaplan-Meier analysis of our cohort of surgically resected pancreatic cancers 
indicates no association between SMAD6 status and survival.  B) Kaplan-Meier analysis 
of the Stage III patients alone suggests that SMAD6 may confer a survival disadvantage 




Table 19.  Relationship between SMAD4 status and SMAD4 status in primary pancreatic 
cancers at rapid autopsy. 
 Low SMAD6 N=(13) High SMAD6 (N=23) p 
SMAD4 Status 
     Intact 















Figure 27.  The impact of SMAD6 on pancreatic cancer metastasis. 
Immunohistochemistry for SMAD6 was performed on pancreatic cancers from autopsy 
patients.  The degree of metastasis at autopsy (Low – fewer than 100 metastases; 
Widespread – greater than 100 metastases) was correlated to the level of SMAD6 
expression.  High SMAD6 expression was associated with widely metastatic disease 









Figure 28.  Effect of SMAD6 on TGF-β and BMP activity. 
Pa03 and Pa04 cells were transfected for SMAD6 overexpression, along with luciferase 
reporters specific for A) TGF-β and B) BMP response.  Data are presented such that the 
wild-type to mutant promoter ratio is set to 1. Pathway activity is presented as the fold 
increase in luciferase levels after addition of ligand (e.g. SBE + TGF-β/mSBE + TGF-β).  
Error bars represent standard error of the mean.  C)  Pa03 and Pa04 cells were transfected 
for SMAD6 overexpression and stimulated with BMP-2 ligand.  ID1 levels are increased 







Figure 29.  SMAD6 binds to the ID1 promoter. 
A) Pa03 and Pa04 cells were transfected for SMAD6 overexpression and stimulated with 
BMP-2 ligand.  The level of p-SMAD1/5/8 was measured by immunoblotting; 
phosphorylation of SMAD1/5/8 remains unchanged upon expression of SMAD6.  B) 
MiaPaCa2 and Pa03 cells were transfected with CS2-FLAG-SMAD6 or left 
untransfected.  Chromatin immunoprecipitation was performed against the FLAG epitope 
in both conditions.  Enrichment of SMAD6 on the ID1 promoter was determined using 
quantitative real-time PCR and compared to a pull-down of the FLAG-epitope in the 
untransfected cells.  C) Treatment of Pa03 cells with 10 ng/mL trichostatin A (TSA) 
results in a buildup of Acetylated Histone H2A.  D) SMAD6 was transiently 
overexpressed in Pa03 cells.  These cells were treated with either DMSO (Vehicle) or 
TSA and were simultaneously stimulated with BMP-2 ligand.  Treatment with TSA did 
not significantly change the level of ID1 transcription, measured by luciferase reporter.  







Figure 30.  Effects of BMP on pancreatic cancer cell behavior. 
A) Differences in cell viability before and after BMP stimulation were determined by 
MTT assay in MiaPaCa2 cells.  BMP treatment did not phenocopy SMAD6 knockdown: 
BMP-2 treatment increased cell viability.  B) Differences in cell viability with and 
without BMP blockade was determined by MTT assay in Pa03 cells.  BMP inhibition did 
not phenocopy SMAD6 overexpression: BMP-2/4 inhibition had no effect on cell 
viability. C) Differences is cell invasiveness before and after BMP stimulation were 
determined in MiaPaCa2 cells.  BMP treatment did not phenocopy SMAD6 knockdown: 
BMP-2 treatment had no effect on invasion.  D) Differences in cell invasiveness with and 
without BMP blockade was in Pa03 cells.  BMP inhibition did not phenocopy SMAD6 
overexpression: BMP-2/4 inhibition had no effect on invasion. E)  Differences in cell 
viability were determined by MTT assay after SMAD6 overexpression.  Overexpression 
of Smad6 increases cell viability in Pa03 cells.  F)  Differences in cell migration capacity 
were determined after SMAD6 overexpression.  For Pa01, cells displayed increased 
migration after SMAD6 knockdown (p=0.0002).  All significance was calculated by 





Figure 31.  Baseline levels of SMAD6 in the cytoplasm and nucleus of pancreatic 
cancer cells. 
The cellular localization of SMAD6 in MiaPaCa2 and Panc1 cells (A) and Pa03 and Pa04 
Control and SMAD6 cells (B) was determined by subcellular fractionation followed by 
immunoblotting for SMAD6 with and without BMP stimulation.  Cells were serum-
starved for 24 hours prior to treatment with BMP-2.  Both native and overexpressed 





















 As a result of our observation that SMAD4 loss was associated with an increased 
metastatic burden in pancreatic cancer (42), our studies were aimed at deciphering the 
mechanism through which loss of TGF-β and BMP signaling led to this clinical 
phenomenon.  As such, we focused, specifically, on the effects of SMAD4 loss as well 
as, broadly, the roles of TGF-β and BMP signaling in pancreatic cancer. Through the 
latter, we identified SMAD6, previously characterized as an inhibitor of these pathways 
(74,75), as a protein of interest in pancreatic cancer. 
 
SMAD4 
 In order to better understand the role of SMAD4 in pancreatic cancer metastasis, 
we generated isogenic cell lines (both parental “pooled” lines and those derived from 
single cells) for SMAD4 expression (Figure 2, Figure 4).  Use of these isogenic cell lines 
yielded interesting observations regarding the effect of SMAD4 on cell behavior in vitro. 
Cells re-expressing SMAD4 exhibited a reduced proliferation rate (Figure 5) as well as 
degrees of migration (Figure 6A) and invasion (Figure 6B).  These properties support 
previous xenograft studies indicating that SMAD4 loss increases tumor growth and 
angiogenesis (89-91), as well as the clinical observations that SMAD4 loss portends a 
shortened survival (93,94) and increased metastasis (42).  Still, these conclusions about 
such an important component of TGF-β and BMP signaling disagree with the findings 
that stimulation with TGF-β and BMP promotes an epithelial-mesenchymal transition in 
vitro, a property considered to be reminiscent of a metastatic phenotype (95-97,105-107).  




that SMAD4 loss reroutes the TGF-β/BMP signal through an alternative, oncogenic 
pathway.  Sure enough, screening our pooled isogenic cell lines for differential pathway 
activation indicated that the ERK and Pi3K pathways were preferentially activated by 
TGF-β in the absence of SMAD4 (Figure 3).  However, we were unable to confirm these 
observations in a cohort of surgically resected pancreatic cancers with known SMAD4 
status (Table 5, Table 6).  Additional study will, hopefully, shed light on whether there is 
an alternative pathway that is activated by TGF-β ligands in the absence of SMAD4 in 
pancreatic cancers.  There are a number of additional pathways that have been reported to 
act as SMAD-independent TGF-β responses (123-126,128).  Furthermore, it is possible 
that our patient cohort was too small to capture a true relationship, if any, between 
SMAD4 status and activation of ERK and Pi3K in pancreatic cancers. 
 Given that it is lost in approximately half of pancreatic cancers (33), SMAD4 
would be an excellent marker to guide treatment of this disease.  In collaboration with 
Drs. Yunfeng Cui and James Eshleman, we tested this hypothesis in vitro and we 
published these results (131).  An association was made between cell lines of known 
SMAD4 status and the efficacy of irinotecan (Figure 10, Table 7, Table 8) and cisplatin 
(Figure 11A, Table 7, Table 8).  In order to further confirm these observations, SMAD4-
isogenic cell lines, described above, were used to study the ability of these agents to kill 
pancreatic cancer cells in the preferential presence or absence of SMAD4.  As shown in 
Figure 12 and Table 9, cells with loss of SMAD4 were more sensitive to cisplatin and 
irinotecan and more resistant to gemcitabine.  These phenomena, particularly those of 
cisplatin and gemcitabine, were correlated with the degree to which the TGF-β pathway 




are statistically significant, it must be noted that they are small.  Further study will be 
required to parse out the true utility of SMAD4 status as a guide for chemotherapy 
treatment.  Mouse experiments are planned to validate these results in vivo.   
 
SMAD6 
In an attempt to better understand the nature of TGF-β and BMP signaling in 
pancreatic cancer, we performed luciferase assays specific for these pathways on a panel 
of pancreatic cancer cell lines that had been identified as having no mutations in pathway 
components.  As shown in Figure 14, there was a high degree of variability in the 
activities of these pathways in these cell lines, with many cell lines displaying little to no 
signaling activity.  We, therefore, sought to determine a rationale for the non-genetic 
inhibition of TGF-β and BMP.  Despite reports to the contrary in other cell types 
(57,157,158), we found neither oncogenic KRAS nor downstream MEK signaling to 
significantly impinge on the activation of these pathways in our pancreatic cell lines 
(Figure 15, Figure 16).  Rather, through a screen of known TGF-β and BMP antagonists, 
we identified SMAD6 as a promising candidate for further study, based on its extreme 
differential expression in our cell lines and, subsequently, in pancreatic cancer tissue 
(Figure 17, Figure 18). 
Interestingly, several sequencing studies have been completed in pancreatic 
cancer, comprising 135 patients, and not a single SMAD6 mutation was identified 
(21,22,161).  As such, we concluded that the regulation of SMAD6 must be epigenetic.  




pancreatic cancers (21).  However, in our cell line panel, the levels of SMAD6 transcript 
did not correspond to the level of SMAD6 protein (Figure 19), indicating that 
transcriptional control is not the means for the differential regulation of SMAD6.  Rather, 
we found that treatment of SMAD6-negative cell lines with MG132, a proteasome 
inhibitor (164), restored the expression of SMAD6 (Figure 20).  Therefore, we conclude 
that SMAD6 is regulated through aberrant proteolytic degradation.  The underlying cause 
for this phenomenon, however, remains unclear.  Further study will illuminate the factor 
or factors responsible for the loss of SMAD6 degradation in pancreatic cancer; recently, a 
screen for SMAD6 binding partners was completed, and several proteins that function in 
modulation of ubiquitination were determined to bind SMAD6 (171).  It is conceivable 
that one or many of these factors is responsible for the aberrant expression of SMAD6 in 
pancreatic cancer, with the possibility that there exist patient-specific regulatory errors in 
this process. 
Given that, in theory, SMAD4 loss and SMAD6 elevation would both result in 
loss of TGF-β and BMP signaling, we hypothesized that the increased SMAD6 
expression would phenocopy SMAD4 loss.  Indeed, we have associated SMAD6 
expression with an increase in migration (Figure 24) and invasion (Figure 25); 
proliferation also appears to be impacted by SMAD6, although to a lesser extent in Panc1 
than in MiaPaCa2 and Pa03 (Figure 22).  Furthermore, we have shown a link between 
elevated SMAD6 expression and metastatic burden in pancreatic cancer patients at 
autopsy, similar to SMAD4 loss (42) (Figure 27).  We find it noteworthy that the clearest 
effects of SMAD6 on pancreatic cancer cell behavior (migration and invasion) most 




metastasis (Figure 27).  However, the association that we have made between SMAD6 
and metastasis is correlative, at this point.  We aim to perform in vivo assays using 
SMAD6-modulated cell lines (overexpressed or knocked down) to determine if SMAD6 
expression can promote metastasis.  In addition, given the associations that we have made 
between SMAD6 protein levels and cell behavior, it is our hope that SMAD6 can be 
studied in the context of chemosensitivity.  Given the high degree to which it is expressed 
in pancreatic cancer, there would be a great clinical boon to determining if SMAD6 can 
be a marker for guiding therapy. 
Given the seemingly parallel downstream effects of SMAD4 loss and SMAD6 
elevation, we hypothesized that it was through inhibition of TGF-β superfamily signaling 
that SMAD6 exerts its effects in pancreatic cancer.  In order to validate that SMAD6, 
indeed, functions through the inhibition of TGF-β and/or BMP signaling in pancreatic 
cancer, we performed luciferase assays specific for these pathways on cell lines in which 
SMAD6 was transiently overexpressed.  It appears that SMAD6 does not significantly 
impact TGF-β signaling (Figure 28A) but, instead, inhibits the BMP response (Figure 
28B).  However, when we analyzed the inhibition of SMAD1/5/8 phosphorylation, 
SMAD6 did not seem to have an effect (Figure 29).  Rather, SMAD6 binds to the 
promoter region of ID1 (Figure 29B) and has previously been shown to inhibit BMP-
mediated transcription (76,112,113).   
Subsequently, we aimed to verify that BMP inhibition was the mechanism 
through which SMAD6 conferred behavioral changes upon pancreatic cancer cells. 
Unexpectedly, stimulation or inhibition of BMP activity in MiaPaCa2 and Pa03 cells did 




did SMAD6 modulation.  Furthermore, SMAD6 overexpression yielded functional 
changes in the absence of SMAD4 – overexpression of SMAD6 increased the migratory 
capacity of Pa01, a cell line with a homozygous deletion of SMAD4 (21) (Figure 30F).  
Thus, we conclude that SMAD6 acts independently of BMP inhibition in the biology of 
pancreatic cancer. 
While the canonical function of SMAD6 has been the inhibition of BMP 
signaling, there have been other functions ascribed to this protein.  Notably, as 
aforementioned, SMAD6 has been shown to have transcriptional repressive capability 
(76,112,113).  We observed a striking trend in our immunohistochemical analyses of 
SMAD6: cases in which SMAD6 was overexpressed displayed strong nuclear positivity 
(Figure 18).  In agreement with studies by Bai et al. and Lin et al., we were able to 
demonstrate that SMAD6 is constitutively present in the nuclei of pancreatic cancer cells, 
regardless of stimulation with BMP ligand (Figure 31).  That SMAD6 is constitutively 
present in the nucleus suggests that it has nuclear functions separate from inhibiting BMP 
responses.  We hypothesize, therefore, that the BMP-independent actions of SMAD6 in 
the nuclei of pancreatic cells is the mechanism that contributes to altered pancreatic 
cancer cell behavior. 
In an attempt to further understand the nuclear role of SMAD6, we performed 
ChIP-seq analysis on MiaPaCa2 and Pa03 cells expressing FLAG-SMAD6 (Figure 29B) 
to identify novel, BMP-independent binding regions in the genome.  However, the data 
were, largely, inconclusive.  Still, there were several putative peaks identified in both 
MiaPaCa2 and Pa03 cells (data not shown).  Of the peaks identified, one target, ErbB4, is 




identified in a previous microarray study as being one of the major pathways impacted by 
SMAD6 modulation (111).  Given the putative function of SMAD6 as a transcriptional 
repressor, it is of note that ERBB4 expression is reduced in pancreatic cancer compared 
to normal pancreatic tissue, and its expression was not detected in any metastatic 
pancreatic cancers analyzed (196,197).  These results align with our observation that 
increased SMAD6 expression correlates with increased metastasis.  Further study will 
continue to identify the true target genes of SMAD6 in pancreatic cancer.  In addition, 
experiments to study the behavioral effects of blocking the DNA-binding capacity of 
SMAD6 are planned. 
In addition, the mechanism by which SMAD6 enters the nucleus remains 
unknown.  An analysis of the protein sequence of SMAD6 yielded no predicted Nuclear 
Import Sequences (data not shown), suggesting that a binding partner facilitates its entry 
into the nucleus.  Previous work has indicated that SMAD1 was necessary for SMAD6 to 
bind to the ID1 promoter (113).  Therefore, it is possible the BMP-specific R-SMADs act 
to shuttle SMAD6 into the nucleus, given that SMAD6 is known to competitively bind 
these molecules (75).  While SMAD6 has been shown to interact with phosphorylated 
SMAD1, it remains to be seen if native SMAD1 is able to bind to SMAD6, as well, given 
that SMAD1 has been shown to shuttle between the nucleus and cytoplasm in the absence 
of BMP stimulation (75,198).  Further experimentation will, hopefully, shed light on 
these aspects of the nuclear biology of SMAD6 nuclear import. 
Finally, while we have associated the differential expression of SMAD6 with cell 
behavior changes in vitro and an increase in metastasis in patients, the underlying 




performed a microarray analysis of non-small cell lung cancer cells after SMAD6 
knockdown; Ingenuity Pathway Analysis indicated a number of functional categories that 
were significantly changed upon SMAD6 modulation, including cell cycle, cell 
morphology, cellular movement, and cancer (111).  We hope to perform a similar 
experiment to assess the gene expression profiles with and without SMAD6 in pancreatic 
cancer cells in order to better understand the dynamics of SMAD6 expression in this 
context. 
 To sum, we have identified SMAD6 overexpression as a novel factor associated 
with pancreatic cancer metastasis.  More work is certainly necessary to understand the 
true effects of  SMAD6 dysregulation on pancreatic cancer cells.  However, it is our hope 
that this new cancer-associated protein may yield more insight into the biology and 
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